Clinical trial register · European Union · CTIS

EU Clinical Trials Tracker

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV

Source: EMA Clinical Trials Information System (CTIS). Showing the 2556 most recently authorised of 12757 total CTIS records — a stated recency window, not the full historical archive. Synced 03 Nov 2026, 03:17 UTC

2556

Shown in this register

most recently authorised

12,757

Total on CTIS

full historical archive

787

Phase III

within the shown window

Top member states

Spain 1075 France 937 Germany 900 Italy 777 Poland 626 Netherlands 548

Narrow the register

Search within results

Phase

Lead sponsor

Member state

All 28 states

Trials in this register

Phase

Study

Lead sponsor

Area

Member states

Decision

Phase II

Effects of a CB1 Receptor Antagonist/Inverse Agonist (Rimonabant) on Walking Ability in Patients in the Chronic Phase of Stroke

2025-521693-33-00Stroke

Sinfatin S.L.

Nervous System Diseases

Spain

17/08/2026

Phase III

C4931007 - A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS

2025-523447-35-02Pneumoccoccal Immunisation

Pfizer Inc.

Bacterial Infections and Mycoses

Spain, Finland, Poland, Germany, Greece, Hungary, Italy

17/08/2026

Phase I/II

A Phase 1/2 Open-label, Multi-center Study to Evaluate the Safety and Clinical Activity of GSK5926371 in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas (B-NHL)

2025-524915-36-00Lymphoma, Non-Hodgkin

Glaxosmithkline Research & Development Limited

Neoplasms

Italy, Germany, Spain, Finland, France

17/08/2026

Phase III

A Phase III, Randomized, Open-label Trial of BNT324 Versus Docetaxel With Prednisone/Prednisolone in Metastatic Castration-resistant Prostate Cancer

2025-524445-27-00Metastatic castration-resistant prostate cancer (mCRPC)

DrugsBNT324·Prednisone·Docetaxel

BioNTech SE

Male Urogenital Diseases

Belgium, Spain, Italy, Poland, Germany, Hungary

17/08/2026

Phase I

A Two-part study to learn the amount of polymyxin E1 in the body over time formed after a single inhaled dose of colistimethate sodium (CMS) in healthy adults (Part 1) and after single inhaled and vein-infused doses of CMS in adults with non‑cystic fibrosis bronchiectasis (NCFB) (Part 2)

2025-524324-22-00Non-cystic fibrosis bronchiectasis

Zambon S.p.A.

Respiratory Tract Diseases

Belgium, Poland, Bulgaria

17/08/2026

Phase III

A Phase III Randomised, Double-Blind, Parallel-Group Study to Assess the Effect of Fixed Dose Combination Laroprovstat/Rosuvastatin Compared with Rosuvastatin on Low-Density Lipoprotein Cholesterol in Patients with Hypercholesterolaemia.

2026-526258-15-00Hypercholesterolaemia

AstraZeneca AB

Nutritional and Metabolic Diseases

Germany

17/08/2026

Phase II

A phase IIa open-label dose-finding study with lead-in phase evaluating the safety, pharmacokinetics, and attenuating effects of trazodone on the consciousness-altering effects of psilocybin in individuals with Treatment-Resistant Depression

2025-523346-27-00Treatment-Resistant Depression

Universita' Degli Studi G. D'Annunzio Di Chieti

Mental Disorders

Italy

14/08/2026

Phase III

The HCC patient-journey study: a prospective, adaptive, master protocol, to assess the value of the available sequences of treatment for patients with advanced hepatocellular carcinoma. The Journey of liver cancer patient - J-LI

2026-525898-39-00Advanced hepatocellular carcinoma

DrugsSorafenib·Regorafenib·Tremelimumab·Cabozantinib

Azienda Sanitaria Locale Napoli 1 Centro

Neoplasms

Italy

14/08/2026

Phase II

Denosumab or Zoledronic acid for erosive hand osteoarthritis (EHOA) in patients with osteoporosis a randomized controlled trial (ZODIAC trial)

2026-526828-41-00Erosive hand osteoarthritis (EHOA)

DrugsZoledronic Acid·Denosumab

Azienda Ospedaliera Universitaria Integrata Verona

Musculoskeletal Diseases

Italy

14/08/2026

Phase II

A Phase 2, randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of CRD-4730 in patients with heart failure with reduced ejection fraction (HFREF) (CALIBRATE-HF)

2025-525033-31-00heart failure

DrugCRD-4730

Cardurion Pharmaceuticals Inc.

Cardiovascular Diseases

Latvia, Slovakia, Lithuania, Hungary, Italy, Netherlands, Spain, Poland, Bulgaria, Czechia

14/08/2026

Phase I

A study to test how BI 3034701 is taken up and processed by the body in healthy men with normal weight or overweight

2026-525825-19-00Healthy

Boehringer Ingelheim International GmbH

Not possible to specify

Hungary

14/08/2026

Phase I

Bioequivalence of Estradiol 10 mcg Vaginal Tablets in Healthy Women Participants.

2026-526477-42-00Not applicable (submitted trial is a bioavailability trial …

Laboratorios Leon Farma S.A.

Female Urogenital Diseases and Pregnancy Complications

Czechia

14/08/2026

Phase II

A Phase 2 Randomized Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Three Doses of Frevecitinib (KN-002) in Patients with Severe Asthma not Adequately Controlled with Medium to High Dose ICS/LABA Therapy (PANAIRAMA)

2023-509125-41-00Severe asthma

DrugSalbutamol

Kinaset Therapeutics Inc.

Respiratory Tract Diseases

Czechia, Bulgaria, Romania, Hungary, Germany, Poland, Greece

14/08/2026

Phase II

An Exploratory Phase 2 Multicenter, Double-blind, Randomized, Placebo controlled, Parallel Group Study to Investigate the Safety, Tolerability, and Efficacy of TML-6 in Early Alzheimer’s Disease

2026-525539-18-00Early Alzheimer’s Disease

Merry Life Biomedical Co. Ltd.

Nervous System Diseases

Sweden

14/08/2026

Phase I/II

An open-label phase I/II, single-center, interventional singlearm basket trial of UKT-CART19.1 in patients with relapsed/refractory autoimmune diseases

2024-519491-60-00ANCA associated vasculitis (AAV), Immune thrombocytopenic p…

Universitaetsklinikum Tuebingen AöR

Immune System Diseases

Germany

14/08/2026

Phase III

A Phase 3, Randomized, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Adults With Previously Untreated Primary Immune Thrombocytopenia (ITP)

2026-525454-11-00Diagnosis of primary ITP according to the 2019 Internationa…

Amgen Inc.

Hemic and Lymphatic Diseases

Spain, Hungary, Germany

14/08/2026

Phase II

TIPS : Immunomodulatory Treatment of Interstitial Lung Disease Associated with Surfactant related Gene Mutations

2026-525336-41-00Interstitial Lung Disease

DrugsAzithromycin·Hydroxychloroquine·Prednisolone·Prednisone

Assistance Publique Hopitaux De Paris

Respiratory Tract Diseases

France

14/08/2026

Phase II

[⁶⁸Ga]Ga-HKG301 PET/CT for staging and restaging patients with primary breast cancer: a phase II study (FAPILOUS)

2025-521324-29-00Primary breast cancer

DrugAAA514

Odense University Hospital

Neoplasms

Denmark

14/08/2026

Phase II

Quantitative Unified Assessment of Novel Triplet therapy and Unconventional Maintenance with Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer: A Phase II Pilot Trial

2026-525550-11-00Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

DrugXofigo

Alianza Multidisciplinar Para La Investigacion De Los Tumores Genitourinarios Guard

Male Urogenital Diseases

Spain

14/08/2026

Phase IV

Phase IV Low Intervention Clinical Trial to Study Biomarkers of "inflammageing" and Senescence in Pre-diabetic Patients Treated with Metformin: A Study nested within the project “NLRP3 Inflammasome at the Crossroad of Vascular Inflammageing: A Novel Target for Senomorphic Drugs”.

2026-527080-15-00Pre-diabetic Patients

Universidad Autonoma De Madrid

Metabolism

Spain

14/08/2026

Phase III

Phase II randomized trial evaluating modified FOLFIRINOX and FOLFOX in the treatment of locally advanced or metastatic small bowel adenocarcinoma [FIRE-12]

2025-524131-39-00locally advanced or metastatic small bowel adenocarcinoma

DrugsCalcium folinate·Irinotecan·Oxaliplatin

Charite Universitaetsmedizin Berlin KöR

Digestive System Diseases

Germany

13/08/2026

Phase I

A Phase 1b Study of ZN-c3 in Combination with Chemotherapy or Bevacizumab in Subjects with Ovarian, Peritoneal, or Fallopian Tube Cancer

2025-524868-38-00Ovarian, Peritoneal, or Fallopian Tube Cancer

K-Group Beta Inc.

Neoplasms

France

13/08/2026

Phase II

Multicenter, randomized, open-label non-inferiority trial, comparing two antibiotic therapy periods (3 versus 7 days) in patients with mild leptospirosis and seen at the hospital in 5 French overseas departments (Martinique, Guadeloupe, French Guiana, Reunion, Mayotte)

2024-518027-30-00leptospirosis

DrugDoxycycline

CHU De Martinique

Bacterial Infections and Mycoses

France

13/08/2026

Phase II

A TWO-STAGE, SINGLE-ARM, PHASE II STUDY OF ZONGERTINIB PLUS FULVESTRANT IN PARTICIPANTS WITH HORMONE RECEPTOR-POSITIVE/HER2-NEGATIVE ADVANCED BREAST CANCER HARBORING HER2 MUTATIONS (AGATHA)

2026-525328-10-00HR-positive/HER2-negative advanced breast cancer

DrugsZongertinib·Goserelin·Fulvestrant

Medica Scientia Innovation Research S.L.

Neoplasms

Spain, Italy, Germany

13/08/2026

Phase I/II

A two-part, randomised, double-blind, placebo-controlled, parallel-group, 12week trial investigating the safety, tolerability, pharmacokinetics and efficacy of XEN-D0501 in obese participants

2026-525869-42-00Obesity

Pila Pharma AB

Nutritional and Metabolic Diseases

Sweden

13/08/2026

Phase III

SERAFA-1: A Single arm, Open label, Multicentre, Phase IIIb Study Of Camizestrant plus Ribociclib in 1st line Treatment of ER-positive, HER2-negative Advanced Breast Cancer Patients

2025-523444-12-00Breast Cancer

AstraZeneca AB

Neoplasms

Poland, Spain, France, Germany, Italy

13/08/2026

Phase IV

A randomized, double blind, placebo-controlled study comparing the efficacy of dupilumab to standard of care (SOC) treatment following hospitalization for a COPD exacerbation

2025-524392-23-00Chronic obstructive pulmonary disease (COPD)

DrugDupilumab

Regeneron Pharmaceuticals Inc.

Respiratory Tract Diseases

Belgium, Italy, Spain

13/08/2026

Phase II

AN OPEN LABEL, SINGLE ARM, EXPLORATIVE TRIAL TO EVALUATE EFFICACY AND SAFETY OF BEROTRALSTAT IN PREVENTING ANGIOEDEMA ATTACKS IN SUBJECTS WITH ACQUIRED ANGIOEDEMA DUE TO C1 INHIBITOR DEFICIENCY (AAE)

2025-524747-13-00Acquired angioedema due to C1 inhibitor deficiency

Policlinico San Donato S.p.A.

Genetic Phenomena

Italy

12/08/2026

Phase III

International, multicenter, blinded phase III clinical trial to assess the diagnostic efficacy of the skin prick test from ROXALL (SPT-RX) with different allergen extract solutions for in vivo diagnosis of IgE mediated allergies

2025-524676-32-00Patients suffering from rhinitis / rhinoconjunctivitis, wit…

ROXALL Medizin GmbH

Diagnosis

Germany, Spain

12/08/2026

Phase II

A RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, CLINICAL TRIAL OF COLCHICINE IN AMYOTROPHIC LATERAL SCLEROSIS (CO-ALS II)

2026-526460-20-00AMYOTROPHIC LATERAL SCLEROSIS

Azienda Ospedaliero Universitaria Di Modena

Musculoskeletal Diseases

Italy

12/08/2026

Phase I

Bioavailability Comparison of Finerenone 20 mg Tablets (Test vs. Comparator Product).

2026-527382-30-00Comparative bioavailability study under fasting conditions.

ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.

Cardiovascular Diseases

Czechia

12/08/2026

Phase II

A phase II, single arm two-phase, clinical study of individually adapted systemic radioligand therapy with 177Lu-PSMA I&T for patients with metastatic, castration-resistant prostate cancer

2026-527110-23-00Prostate cancer

Region Uppsala

Male Urogenital Diseases

Sweden

12/08/2026

Phase III

Prognostic value assessment of PSMA-T4 examination in the group of patients with triple-negative breast cancer (TNBC) qualified to radical therapy

2025-525110-29-01triple-negative breast cancer

Narodowe Centrum Badan Jadrowych

Neoplasms

Poland

12/08/2026

Phase II

Evaluation of the efficacy, safety, and tolerability of lutetium-177-labeled PSMA ligand in patients with progression of adenoid cystic carcinoma originating from the salivary glands - an open, non-commercial clinical trial

2026-525776-26-00adenoid cystic carcinoma of the salivary glands

Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy

Otorhinolaryngologic Diseases

Poland

12/08/2026

Phase I/II

Preventive Dendritic Cell vaccination for Lynch Syndrome (PREVENT-Lynch)

2025-524046-10-00Lynch Syndrome

Radboud universitair medisch centrum Stichting

Digestive System Diseases

Netherlands

12/08/2026

Phase I

A Study to Assess the Effects of Probenecid on the Pharmacokinetics of Mirdametinib and its Metabolites in Healthy Participants

2026-526403-30-00This clinical trial is performed in healthy participants; t…

Merck Healthcare KGaA

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Germany

12/08/2026

Phase III

Premedication with dexamethasone for preventing interstitial lung disease in patients with breast cancer treated with trastuzumab deruxtecan

2025-521798-15-00Breast Cancer

DrugDexamethasone

Istituto Di Ricerche Farmacologiche Mario Negri

Neoplasms

Italy

11/08/2026

Phase I

A dose escalation and expansion study of XB010 as a single agent and combination therapy in subjects with locally advanced or metastatic solid tumors

2025-524805-34-00Locally Advanced or Metastatic Solid Tumors

Exelixis Inc.

Neoplasms

Italy, Netherlands, France, Spain

11/08/2026

Phase I

Phase 1 Study of PF-08046033 in Advanced Solid Tumors

2025-522532-14-00Advanced solid tumors

Pfizer Inc.

Neoplasms

Netherlands, France, Spain

11/08/2026

Phase IV

Patient-Controlled Anesthesia for endoscopic Procedural Sedation – PCAPS study

2025-524859-31-00Adenoma

DrugsMidazolam·Propofol

Karolinska Institutet

Digestive System Diseases

Sweden

11/08/2026

Phase I/II

Bioequivalence clinical trial of two formulations of quetiapine.

2026-527162-72-00Healthy participants

Laboratorios Alter S.A.

Mental Disorders

Spain

11/08/2026

Phase III

A multicentre randomised study on percutaneous stellate ganglion block as first line treatment in patients with electrical storm: the STAR 2 study

2024-520387-34-01electrical storm

Fondazione IRCCS Policlinico San Matteo

Cardiovascular Diseases

Italy

11/08/2026

Phase II

Valproic acid and lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma

2026-525733-24-00Recurrent and/or Metastatic Adenoid Cystic Carcinom

DrugsSodium valproate·Lenvatinib

Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia

Neoplasms

Italy

11/08/2026

Phase II

SDH-FLUX - Development of a new biomarker for tumor development in patients with SDHx mutation by in vivo fluxomics

2023-506001-19-00paraganglioma or pheochromocytoma with surgical indication

Assistance Publique Hopitaux De Paris

Hormonal diseases

France

10/08/2026

Phase III

AVISO - Assessment of Flecainide versus Bisoprolol as First-Line Treatment for Premature Ventricular Contractions: a Multicenter Randomized Clinical Trial

2025-524584-20-00Premature ventricular contractions (PVC)

DrugsBisoprolol·Flecainide

Assistance Publique Hopitaux De Paris

Cardiovascular Diseases

France

10/08/2026

Phase II

A Phase 2 Multicentric Randomized Double-Blinded Efficacy and Safety Clinical Trial Comparing Several Doses of Aganirsen Eye Drops Emulsion to Extend Intravitreal Aflibercept Treatment Interval in Wet Age-Related Macular Degeneration (wAMD) Patients - SKY2 Study

2026-526775-27-00Wet Age-Related Macular Degeneration (wAMD) Patients

DrugAflibercept

Laboratoires Kol

Eye Diseases

France

10/08/2026

Phase I

A Phase 1, Open-Label, Multicenter Study of INCA036978 in Participants With Myeloproliferative Neoplasms

2026-525217-31-00Myeloproliferative Neoplasms

Incyte Corp.

Neoplasms

Italy, Belgium, Germany, France, Spain

10/08/2026

Phase I/II

Evaluation of Interference and Synergy of Anti-Circumsporozoite Antibodies on GA2-induced Immunity

2026-525353-37-00Plasmodium falciparum malaria

Leids Universitair Medisch Centrum (LUMC)

Parasitic Diseases

Netherlands

10/08/2026

Phase I

A research study looking into how a single dose of the medicine NNC0537-1482 moves through the body of participants with normal or reduced kidney function

2026-525271-57-00Heart failure with preserved ejection fraction

Novo Nordisk A/S

Cardiovascular Diseases

Germany

10/08/2026

Phase II

Effects of a CB1 Antagonist/Reverse Agonist (Rimonabant) on Functional Recovery in Stroke Patients During Subacute Phase.

2025-521689-86-00Stroke

Sinfatin S.L.

Nervous System Diseases

Spain

10/08/2026

Phase I

A Phase 1 Trial of GEN1119 in Participants with Solid Tumors

2026-525610-62-00Solid Tumors

Genmab A/S

Neoplasms

Spain, France

10/08/2026

Phase III

A single-arm, multicenter, phase III study to assess efficacy, pharmacokinetics, safety and tolerability of atrasentan in pediatric patients of 2 to <18 years of age with primary immunoglobulin A nephropathy (IgAN)

2025-522824-29-00Primary IgAN

Novartis Pharma AG

Immune system processes

France, Spain

10/08/2026

Phase I

Bioequivalence study 3 to compare pharmacokinetics of Parkinson´s disease drugs in healthy volunteers

2026-525450-11-00Parkinson's desease

Orion Corporation

Nervous System Diseases

Czechia

10/08/2026

Phase II

A Phase 2, Multicenter, Open-Label Study of Zolacabtagene Autoleucel (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants with Chronic Immune Thrombocytopenia (cITP) and Autoimmune Hemolytic Anemia (AIHA) (Breakfree-AiCE)

2025-524993-41-00Chronic Immune Thrombocytopenia (cITP) and Autoimmune Hemol…

Celgene Corp.

Immune System Diseases

Germany, Denmark

10/08/2026

Phase III

A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Monotherapy Study to Evaluate Efficacy of Roluperidone on Negative Symptoms in Adult Subjects with Schizophrenia, Followed by a 40-Week, Randomized, Double-Dummy Phase to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications

2026-525925-19-00Schizophrenia with negative symptoms

DrugsAripiprazole·Risperidone·Olanzapine

Minerva Neurosciences Inc.

Mental Disorders

Bulgaria, Romania

10/08/2026

Phase III

Efficacy and safety of once daily oral semaglutide in adults with overweight or obesity

2025-524626-18-00Overweight and obesity

Novo Nordisk A/S

Nutritional and Metabolic Diseases

Netherlands, Belgium, Greece, Poland, Spain, Denmark, France, Bulgaria, Sweden

10/08/2026

Phase IV

The RHINOME study

2026-527032-14-00Severe asthma

Region Hovedstaden

Respiratory Tract Diseases

Denmark

10/08/2026

Phase II

An Investigator-Initiated, Descriptive, Proof-of-Concept, Open-Label Pilot Study Focusing on Topical JAK Inhibition as a Novel Treatment of Cutaneous T-Cell Lymphoma

2025-523472-23-01Cutaneous T-cell lymphoma (CTCL) Mycosis fungoides

DrugDelgocitinib

Region Midtjylland

Therapeutics

Denmark

10/08/2026

Phase III

A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves’ Disease Inadequately Controlled With Antithyroid Drugs

2025-523333-26-00Graves' Disease (GD)

Argenx

Hormonal diseases

Italy, Czechia, Spain, Denmark, Belgium, Romania, Latvia, France, Germany, Greece, Sweden, Poland, Lithuania, Bulgaria

07/08/2026

Phase III

Topical Clobetasol Propionate for Inflammatory Hand osteoarthritis: A randomized trial versus placebo.(PROCLAME)

2025-520678-20-00Adult patients with symptomatic and inflammatory Hand osteo…

DrugClobetasol Propionate

Assistance Publique Hopitaux De Paris

Musculoskeletal Diseases

France

07/08/2026

Phase IV

HORUS-Cytomegalovirus Open Proof-of-concept Exploratory trial

2025-524845-28-00Cytomegalovirus infection in solid-organ transplant recipie…

DrugEverolimus

Centre Hospitalier Universitaire Vaudois

Virus Diseases

France, Spain

07/08/2026

Phase IV

A Phase 4, Pragmatic, Randomized Trial to Evaluate the Effectiveness of An Influenza/COVID-19 Vaccine (mCombriax [mRNA-1083]) in Adults ≥ 65 Years (DAN-COMBO)

2026-526720-49-00SARS-CoV-2 infection, Influenza infection

Gentofte Hospital, Moderna Inc.

Virus Diseases

Denmark, Spain

07/08/2026

Phase I

A study in healthy men to test whether carbamazepine influences the amount of verducatib in the blood

2026-525821-19-00Healthy

Boehringer Ingelheim International GmbH

Not possible to specify

Germany

07/08/2026

Phase I

A study in healthy people to test how Zongertinib is taken up in the body when given as tablets made by two different manufacturers with or without food

2026-525696-77-00Healthy

Boehringer Ingelheim International GmbH

Not possible to specify

Germany

07/08/2026

Phase IV

CLINIC-CURE, a pilot exploratory clinical trial of analytical treatment interruption in people with HIV with a highly favorable profile

2026-526395-23-00HIV

DrugEmtricitabine

Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer

Virus Diseases

Spain

06/08/2026

Phase III

BETARGET : Randomized trial of individualizing BETA-lactam taRGET combining therapeutic drug monitoring, minimal inhibitory concentration and model-based dose adjustment, in Intensive Care Units patients with gram negative bacilli infection

2025-522819-42-01sepsis

DrugsCefotaxime·Ceftazidime·Meropenem·Amoxicillin

Centre Hospitalier Universitaire De Rennes

Bacterial Infections and Mycoses

France

06/08/2026

Phase II

[22961] A placebo-controlled, parallel-group, double blind, randomized, multi-cohort Phase 2 study to investigate efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of BAY 3670549 in adult participants with atrial fibrillation.

2025-523807-31-00Atrial fibrillation

Bayer AG

Cardiovascular Diseases

Belgium, Netherlands, Germany, Poland, Italy, Hungary, Bulgaria

06/08/2026

Phase I

A Randomized, Open label, Single Center, Single Oral Dose, Four Treatment, Four Period, Four Sequence, Crossover Bioavailability Study of Haleon Immediate Release Tablets 2X (paracetamol/naproxen 500 mg/125 mg) vs. Panadol Advance Tablets 2X (paracetamol 500 mg), Naprosyn Tablets 1X (naproxen 250 mg), administered individually in fasted conditions and Haleon Immediate Release Tablets 2X (paracetamol/naproxen 500 mg/125 mg) in fed conditions in Healthy Adult Participants

2025-524663-20-00Healthy volunteers, therapeutic indication not studied

Haleon CH SARL

Not possible to specify

Germany

06/08/2026

Phase III

Spironolactone and SGLT2 inhibitor to Address Fontan circulatory failure and Enhance Resilience: The SAFER-Fontan trial

2025-524783-38-00Fontan circulation

UZ Leuven

Cardiovascular Diseases

Belgium

06/08/2026

Phase I

A study in healthy people to compare how 2 different formulations of vicadrostat / empagliflozin tablets are taken up in the body

2025-524773-16-00Healthy

Boehringer Ingelheim International GmbH

Not possible to specify

Germany

06/08/2026

Phase IV

Influence of Doxycycline Use as Prophylaxis for Sexually Transmitted Infections on Bacterial Resistance and Gut Microbiota: MiDoxyR-PEP Study

2025-525150-19-01Colonization by methicillin-resistant S. aureus and gut mic…

Instituto De Investigacion Marques De Valdecilla

Bacterial Infections and Mycoses

Spain

06/08/2026

Phase I/II

Trial to study the safety, pharmacokinetics and preliminary antitumour activity of ODM-216 in patients with cancer

2026-525864-17-00Advanced solid tumours

Orion Corporation

Neoplasms

Spain

06/08/2026

Phase II

VIP-1 : Preclinical type 1 diabetes: the VIP-1 Study

2025-524318-27-00People with stage 1 or stage 2 T1D between the ages of 7 an…

DrugVerapamil

Assistance Publique Hopitaux De Paris

Immune System Diseases

France

05/08/2026

Phase III

A Phase 3, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Cabotegravir Ultra Long-acting Plus Rilpivirine Ultra Long-acting or Cabotegravir Long-acting Plus Rilpivirine Long-acting in Adults and Adolescents with HIV who are Virologically Suppressed on ART

2024-518511-19-00HIV Infections

Viiv Healthcare UK Limited

Immune System Diseases

Spain

05/08/2026

Phase I

An open label, randomized, single-dose, two-treatment, two-sequence, two-period, cross-over pilot comparative bioavailability study comparing Empagliflozin and Metformin f.c. tabs (12.5+1000) mg, VIANEX S.A., Greece versus Synjardy 12.5 mg/1,000 mg film-coated tablets, Boehringer Ingelheim International GmbH, Germany, in healthy male and female volunteers under fasting conditions.

2026-526397-17-00treatment of diabetes

Vianex S.A.

Hormonal diseases

Czechia

05/08/2026

Phase II

A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study of YMI024 to assess efficacy in reducing inflammatory markers, safety, and tolerability in adults with stable coronary artery disease and elevated hsCRP

2026-525974-21-00Chronic Kidney Disease, Heart Failure, Coronary Artery dise…

Novartis Pharma AG

Cardiovascular Diseases

Germany

05/08/2026

Phase III

ROSY-F: Roll-Over Study for Participants Who Have Completed a Previous Study with Benralizumab (Fasenra) and Are Judged by the Investigator to Clinically Benefit from Continued Treatment

2025-523307-29-00Eosinophilic Granulomatosis with Polyangiitis (EGPA), Hyper…

DrugBenralizumab

AstraZeneca AB

Respiratory Tract Diseases

Denmark, Belgium, France, Italy, Netherlands, Austria, Poland

04/08/2026

Phase IV

A Phase IV, Randomized Controlled Trial to Evaluate the Effects of Resistance Training Versus Usual Care on Thigh Muscle Volume During Treatment with the Dual GIP/GLP-1 Receptor Agonist Tirzepatide in Adults with Obesity

2026-526200-69-00Obesity

Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)

Nutritional and Metabolic Diseases

Germany

04/08/2026

Phase II

A Phase IIb Study to Evaluate the Efficacy, Safety, and Tolerability of AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)) (ARGiNAUT)

2025-525016-41-00Idiopathic Pulmonary Fibrosis

AstraZeneca AB

Respiratory Tract Diseases

Poland, Hungary, Netherlands, Germany, Spain, Greece, Bulgaria, Italy, France, Denmark

04/08/2026

Phase III

A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared with Placebo in Adults with Type 2 Diabetes Mellitus on Background Insulin (Eluminate-3)

2025-523935-20-00type 2 diabetes mellitus

AstraZeneca AB

Nutritional and Metabolic Diseases

Poland, Germany, Bulgaria, Czechia

04/08/2026

Phase I

Study in healthy volunteers to evaluate how the body processes Iadademstat and if food affects it

2026-525953-35-00Healthy Volunteers

Oryzon Genomics S.A.

Not possible to specify

Spain

04/08/2026

Phase I

A study of enzomenib investigating potential drug-drug interactions and the effect of liver impairment in adult patients with advanced cancer

2025-524652-63-00Advanced Cancer

Sumitomo Pharma America Inc.

Neoplasms

Spain, Bulgaria, Poland, Romania

04/08/2026

Phase III

A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron compared with Placebo in Adults with Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin (Eluminate-4)

2025-523940-12-00type 2 diabetes mellitus

AstraZeneca AB

Nutritional and Metabolic Diseases

Germany, Bulgaria, Spain, Denmark

03/08/2026

Phase III

A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron and Dapagliflozin in Combination, Compared with Elecoglipron Alone and Dapagliflozin Alone, in Adults with Type 2 Diabetes Mellitus (Eluminate-5)

2025-523941-81-00type 2 diabetes mellitus

AstraZeneca AB

Nutritional and Metabolic Diseases

Slovakia, Poland, Czechia, Germany, Hungary, Greece, Denmark

03/08/2026

Phase IV

Non-inferiority of surgical treatment of cartilage defects of the knee with autologous minced cartilage implantation (AMCI) and matrix-asscociated autologous chondrocyte implantation with respect to KOOS at 24 months (M ACI) - MinCaRCT

2026-526179-49-00Full-thickness cartilage defects of the knee

Medical Center - University Of Freiburg

Musculoskeletal Diseases

Germany

03/08/2026

Phase III

RUBY study « Randomized controlled trial testing the efficacy of corticosteroid therapy versus placebo in fibrotic hypersensitivity pneumonitis.»

2025-521591-64-00Adult patients with a diagnosis of fibrotic Hypersensitivit…

Assistance Publique Hopitaux De Paris

Respiratory Tract Diseases

France

03/08/2026

Phase III

A Randomized Phase 2/3 Study Evaluating the Safety and Efficacy of Pivekimab Sunirine (PVEK) in Combination with Venetoclax and Azacitidine in Adult Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible to Receive Intensive Chemotherapy

2025-523724-47-00Acute Myeloid Leukemia

AbbVie Deutschland GmbH & Co. KG

Neoplasms

France, Austria, Spain

03/08/2026

Phase I

A First-in-Human Study of INCA035784 in Participants With Myeloproliferative Neoplasms

2026-525360-18-00Myeloproliferative Neoplasms

Incyte Corp.

Neoplasms

Italy, Belgium, Germany

03/08/2026

Phase III

A double-blind, randomised, placebo-controlled trial evaluating the efficacy and safety of oral nerandomilast treatment in patients with systemic sclerosis (SSc)

2025-523884-39-00Systemic sclerosis

DrugNerandomilast

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

Skin and Connective Tissue Diseases

Denmark, Hungary, Sweden, Netherlands, Germany, Belgium, France, Greece, Norway, Finland, Czechia, Portugal, Bulgaria, Spain, Austria, Romania, Croatia, Poland, Estonia, Italy, Lithuania

03/08/2026

Phase II

Pharmacodynamic Evaluation of OV329 in Participants with Epilepsy and a Photo-Induced Generalized Epileptiform EEG-Response Phase 2 Proof-of-Concept.

2026-527114-23-00Epilepsy

Ovid Therapeutics Inc.

Nervous System Diseases

Netherlands

03/08/2026

Phase I

Treatment of patients with autoantibody-positive autoimmune diseases and severe interstitial lung fibrosis with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector - a single center Phase I/II clinical trial (HD-CAR-ILD-1)

2024-519592-26-00Therapy-resistant and progressing lung fibrosis in the cour…

Universitaetsklinikum Heidelberg AöR

Immune System Diseases

Germany

03/08/2026

Phase III

A Phase 3, Randomized, Double-blind, and Active‑controlled Multicenter Study to Evaluate the Efficacy and Safety of JNJ‑78934804 in Participants With Moderately to Severely Active Crohn’s Disease

2026-525922-39-00Moderately to Severely Active Crohn’s Disease

Janssen Cilag International

Immune System Diseases

Norway, Romania, Austria, Italy, Slovakia, Germany, Hungary, Netherlands, Belgium, France, Portugal, Czechia, Poland, Spain, Greece

03/08/2026

Phase III

A Phase 3 Randomized, Double-blind, and Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of JNJ-78934804 in Participants with Moderately to Severely Active Ulcerative Colitis

2026-525923-26-00Moderately to Severely Active Ulcerative Colitis

DrugsJNJ-78934804·Guselkumab

Janssen Cilag International

Immune System Diseases

France, Bulgaria, Romania, Slovakia, Norway, Denmark, Greece, Italy, Austria, Poland, Netherlands, Czechia, Germany, Belgium, Spain, Hungary, Portugal

03/08/2026

Phase I

A Phase I Study to Evaluate ELA822

2025-524911-34-00Healthy Volunteers

Electra Therapeutics Inc.

Immune System Diseases

Austria

02/08/2026

Phase II

Botulinum toxin A in the Treatment of Chronic Postsurgical Pain in Lung Cancer Patients: A feasibility study

2026-525669-33-00Chronic postsurgical pain (CPSP)

DrugXeomin

Aalborg University Hospital

Therapeutics

Denmark

01/08/2026

Phase II

The Danish Anorexia Nervosa Psilocybin RCT (DANP-RCT). A Randomised, Active-Placebo-Controlled, Triple-blind, Superiority Study of Psilocybin-Assisted Acceptance and Commitment Therapy (ACT) in the Treatment of Treatment-resistant Anorexia Nervosa.

2025-524939-39-02Anorexia nervosa

DrugPsilocybin

Slagelse Hospital

Mental Disorders

Denmark

01/08/2026

Phase I

A Randomised, Placebo‑Controlled Trial to Assess Effect of IMU‑838 on QT/QTc

2026-526859-54-00Multiple sclerosis

Immunic AG

Nervous System Diseases

Belgium

31/07/2026

Phase I

A study to test how well different doses of BI 3822971 are tolerated by people with advanced cancer (solid tumours)

2026-525785-22-00solid tumours

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

Neoplasms

Spain

31/07/2026

Phase III

Perioperative Intravenous Metamizole in Laparoscopic Cholecystectomy: A rondomized, double blind, clinical trial.

2026-526531-18-00Post operative pain relief in Patients undergoing laparosco…

UZ Leuven

Anesthesia and Analgesia

Belgium

31/07/2026

Phase II

An Open-Label Phase IIa Trial Exploring the Safety, Tolerability, and Efficacy of the T Cell Engager OM336 for Desensitization of Kidney Transplant Candidates

2025-523222-40-00End stage renal failure

DrugsDiphenhydramine·Paracetamol·Dexamethasone

Medical University Of Vienna

Pathological Conditions, Signs and Symptoms

Austria

31/07/2026

Phase II

A Multicenter, Open-Label, Long-Term, Safety and Tolerability Extension Study of PTI5803 as adjunctive therapy in patients ≥ 14 years of age with drug-resistant seizures associated to focal cortical dysplasia.

2026-525161-40-00Drug resistant focal epilepsy related to focal cortical dys…

DrugPTI5803

PannTheraPi

Nervous System Diseases

France

31/07/2026

Phase I

Whole body HER2 quantification with 89Zr-Trastuzumab PET/CT to asses Zr-trastuzumab accumulation in HER2-mutated and HER2-overexpressing metastatic non-small cell lung cancer

2026-525568-17-00HER2 mutation positive NSCLC

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Pathological Conditions, Signs and Symptoms

Netherlands

30/07/2026

Phase I/II

A Phase 1b/2a first-in-human, multicentre, randomized, double-blind, placebo-controlled study of multiple ascending dose (Part1) followed by an open-label extension (Part2) to assess the safety, tolerability, and pharmacokinetics of intrathecally administered S233107 in participants with spinocerebellar ataxia type 3

2025-525111-17-00Spinocerebellar ataxia type 3

Institut De Recherches Internationales Servier IRIS

Nervous System Diseases

France, Denmark, Spain, Portugal

30/07/2026

Phase I

Nav 1.8 and 1.7 combo trial

2026-526867-39-00Pain

Niroda Therapeutics Inc.

Nervous System Diseases

Netherlands

30/07/2026

Phase I

Bioequivalence of Tramadol retard 200 mg Prolonged-Release Tablets in Healthy Participants Under Fasting Conditions

2026-525836-41-00Not applicable (submitted trial is a bioavailability trial …

Laboratorios Cinfa S.A.

Nervous System Diseases

Czechia

30/07/2026

Phase III

J3L-MC-EZEJ: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Lepodisiran to Investigate the Effect on Coronary Plaque in Adults With Elevated Lp(a) Who Have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event

2025-524858-34-00Lipoprotein(a), Atherosclerosis, Cardiovascular Diseases

Eli Lilly & Co.

Cardiovascular Diseases

Hungary, Czechia, Spain, Netherlands

30/07/2026

Phase I

Study to assess the plasma concentration of rilzabrutinib given as a tablet to adult participants with severe renal impairment compared to matched participants with normal renal function

2026-525707-27-00Renal Impairment

Sanofi-Aventis Recherche & Developpement

Immune System Diseases

Germany

30/07/2026

Phase III

A Phase III, Multicentre, Randomised, Open-label Study to Compare the Efficacy and Safety of AZD0486 plus Rituximab versus Chemotherapy plus Rituximab in Previously Untreated Participants with Follicular Lymphoma (SOUNDTRACK-F1)

2023-510098-33-01Follicular Lymphoma

DrugsSurovatamig·Bendamustine·Vincristine·Doxorubicin

AstraZeneca AB

Neoplasms

Denmark, Czechia, France, Germany, Hungary, Italy, Spain, Poland

29/07/2026

Phase I

A Phase 1a/1b, multicenter, open-label study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of PLN-101095 alone and in combination with pembrolizumab in adults with advanced or metastatic solid tumors following progression on immune checkpoint inhibitor therapy

2026-526116-36-00Advanced or metastatic solid tumours

Pliant Therapeutics Inc.

Neoplasms

Spain

29/07/2026

Phase III

B-HAPPI: Bipolar disorder and high-dose adjunctive pramipexole for anhedonic depression – a phase III, double-blind, randomized controlled trial

2026-526383-20-00Bipolar disorder

Region Skane

Mental Disorders

Sweden

29/07/2026

Phase I/II

A Phase I/II, randomized, placebo-controlled, multi-arm, dose-finding study to evaluate the safety, efficacy and immunogenicity of an Acne mRNA vaccine candidate in adults with moderate to severe acne 18 to 45 years of age

2025-521740-38-00Acne

DrugAcne mRNA vaccine

Sanofi Vaccines US Inc.

Skin and Connective Tissue Diseases

Spain, Germany, Poland

29/07/2026

Phase IV

Effectiveness of Trazodone on Emotional Blunting in Patients with Major Depressive: a Phase IV, Open-label, clinical study

2025-523267-38-00Major depressive disorder (MDD)

Angelini Pharma Italia Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. Enunciabile Anche Angelini Pharma Italia S.p.A. Angelini Pharma S.p.A. A.C.R.A.F. S.p.A. Acraf S.p.A. Angelini S.p.A. aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.

Mental Disorders

Bulgaria, Poland, Hungary

29/07/2026

Phase III

A Phase III, Randomized, Double-blind, Parallel-group, Placebo controlled, Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Cardiovascular Outcomes in Participants with HFpEF and HFmrEF (Elevate-HF)

2026-526304-79-00Heart failure with preserved ejection fraction (HFpEF) and …

AstraZeneca AB

Cardiovascular Diseases

Spain, Hungary, Germany, Poland, Italy, Bulgaria, Netherlands, Austria, Romania, Sweden, France, Greece, Slovakia, Czechia

29/07/2026

Phase I

An Open-label Phase 1 Study in Healthy Adult Participants to Investigate the Effect of Itraconazole on the Blood Levels of Engasertib

2026-526311-11-00This clinical trial is performed in healthy participants; t…

Vaderis Therapeutics AG

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Germany

29/07/2026

Phase II

A Phase 2 Study of Alisertib in Combination with Paclitaxel in Patients with Small Cell Lung Cancer

2026-525382-47-00Small Cell Lung Cancer (SCLC)

Puma Biotechnology Inc.

Neoplasms

France, Poland, Spain

28/07/2026

Phase I/II

Melanoma-TBK1-inhibitor enhanced Immuno Therapy with Checkpoint Inhibitors: a Phase IB/II Trial in Unresectable Stage III or Stage IV Cutaneous Melanoma

2026-526821-16-00Unresectable Stage III or Stage IV Cutaneous Melanoma

DrugsNivolumab·Pembrolizumab

Karolinska University Hospital

Neoplasms

Sweden

28/07/2026

Phase IV

Comparative study of two vaccination schedules for the subunit Herpes Zoster vaccine in Multiple Sclerosis and Neuromyelitis optica spectrum disease patients treated with anti-CD20 therapy: an open-label randomised controlled trial.

2025-525106-37-00Multiple Sclerosis and Neuromyelitis optica spectrum

DrugsOcrelizumab·Rituximab

Centre Hospitalier Universitaire De Toulouse

Nervous System Diseases

France

28/07/2026

Phase II

OBINUSS - Safety and efficacy of obinutuzumab in systemic sclerosis: a phase II, randomized, double-blinded versus placebo-controlled trial

2025-524003-68-00Patients with newly or active diffuse Systemic sclerosis at…

DrugObinutuzumab

Assistance Publique Hopitaux De Paris

Immune System Diseases

France

28/07/2026

Phase IV

STRategiEs for Antiplatelet Management foLlowIng acute coroNary syndromE (STREAMLINE)

2026-525933-22-00ischemic heart disease

DrugsPrasugrel·Acetylsalicylic acid·Ticagrelor

Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz

Cardiovascular Diseases

Spain, Norway

28/07/2026

Phase I

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination with Bevacizumab in Adult Participants with Ovarian Cancer

2025-522209-40-00Ovarian Cancer

AbbVie Deutschland GmbH & Co. KG

Neoplasms

Portugal, Denmark, Spain, France

27/07/2026

Phase I

A Phase 1 Study of PRT12396 in Participants with Select Myeloproliferative Neoplasms

2026-525484-40-00Post-Essential Thrombocythemia Myelofibrosis, Post-Polycyth…

Prelude Therapeutics Inc.

Neoplasms

Italy, France, Spain

27/07/2026

Phase III

A Randomized Controlled Study Evaluating Short-Term Dual Antiplatelet Therapy with Low-Dose Ticagrelor (60 mg) Followed by Monotherapy versus Standard-Duration Dual Antiplatelet Therapy with Clopidogrel in Patients with Chronic Coronary Syndrome Undergoing Percutaneous Coronary Intervention: the STELAR trial

2026-526368-18-00Chronic Coronary Syndrome in patients undergoing percutaneo…

DrugClopidogrel

Azienda Ospedaliera Universitaria Gaetano Martino Messina

Cardiovascular Diseases

Italy

27/07/2026

Phase I

A first-in-human, randomized, double-blind, placebo-controlled, 3-part study assessing the safety, tolerability, pharmacodynamics and pharmacokinetics of GL0071 after single and repeated ascending subcutaneous doses in healthy normal weight, overweight and obese participants, as well as a 12-week treatment randomized, double blind, placebo-controlled exploratory Proof-of-Concept study in overweight and obese participants.

2025-524233-45-00Type 2 diabetes mellitus, Overweight

Sun Pharmaceutical Industries Limited

Nutritional and Metabolic Diseases

Belgium

27/07/2026

Phase II

A Cancer Research UK Phase II trial of CY-101 given via intratumoural administration in locally advanced or metastatic adrenocortical carcinoma (CLARITY)

2025-522757-19-00LOCALLY ADVANCED OR METASTATIC ADRENOCORTICAL CARCINOMA

Cancer Research UK

Neoplasms

Spain, France, Germany, Norway

27/07/2026

Phase II

A Phase 2 Study Evaluating the Safety and Efficacy of Neoadjuvant Amivantamab in Combination with Lazertinib or Chemotherapy in Resectable EGFR-Mutated Non-Small Cell Lung Cancer

2025-524816-13-00Non-small Cell Lung Cancer

DrugsLazertinib·Amivantamab

Janssen Cilag International

Neoplasms

Spain

27/07/2026

Phase III

A clinical study to compare efficacy and safety of two different doses of CagriSema and semaglutide in participants with obesity with or without type 2 diabetes

2025-522488-14-00Participants with obesity with or without type 2 diabetes

Novo Nordisk A/S

Nutritional and Metabolic Diseases

Greece, Portugal, France, Slovakia, Bulgaria, Netherlands, Romania, Italy, Austria, Poland, Hungary, Spain, Czechia, Belgium

27/07/2026

Phase III

4TAZPower: A Phase 3b/4, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Patients with Genetically Confirmed Barth Syndrome

2025-523837-25-00Barth Syndrome

DrugElamipretide

Stealth Biotherapeutics Inc.

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Ireland, Netherlands, France, Italy

27/07/2026

Phase I/II

Phase I/II Trial to Determine Safety and Efficacy of non-Viral Allogeneic Dual CD123/33-Chimeric Antigen Receptor CIK (CARCIK-CD123/33) Cells in Adult and Pediatric Patients with Relapse/Refractory Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

2025-524977-18-00Acute myeloid leukemia and Blastic plasmacytoid dendritic c…

Fondazione Tettamanti, Fondazione IRCCS San Gerardo Dei Tintori

Neoplasms

Italy

27/07/2026

Phase I

A clinical trial of MK-3868 in healthy participants (MK-3868-001)

2026-526674-17-00Malaria

Merck Sharp & Dohme LLC

Parasitic Diseases

Belgium

27/07/2026

Phase III

A Phase 3 Randomized, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of ABBV-706 versus Standard of Care in Subjects with Relapsed/Refractory Small Cell Lung Cancer (SCLC)

2025-523819-11-00Small Cell Lung Cancer

DrugsABBV-706·Topotecan

AbbVie Deutschland GmbH & Co. KG

Neoplasms

Italy, Greece, Spain, Belgium, France, Austria, Germany

27/07/2026

Phase III

Multi-Center, Placebo-Controlled, Phase 3 Study of Etripamil Nasal Spray (NS) in Patients with Atrial Fibrillation and Rapid Ventricular Rate (RVR). The ReVeRA-301 Trial.

2024-516251-40-01Atrial Fibrillation

Milestone Pharmaceuticals Inc.

Cardiovascular Diseases

Netherlands, Spain

27/07/2026

Phase IV

Within-Patient Comparison of Serum Transthyretin Response to Tafamidis Versus Acoramidis: A Pilot Crossover Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

2026-526526-41-01Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

DrugAcoramidis

Medical University Of Vienna

Cardiovascular Diseases

Austria

27/07/2026

Phase IV

Thromboprophylaxis with apixaban during neoadjuvant therapy for muscle-invasive bladder cancer (ACB): An international randomized controlled trial evaluating apixaban versus no anticoagulation in patients scheduled to undergo radical cystectomy or chemoradiotherapy for muscle-invasive bladder cancer

2024-518861-90-00Venous thromboembolism (in bladder cancer patients)

DrugApixaban

HUS-Yhtymae

Therapeutics

Finland

27/07/2026

Phase I

A study in healthy people to measure how different doses of verducatib affect the heart

2026-525813-30-00Healthy volunteer trial

Boehringer Ingelheim International GmbH

Not possible to specify

Germany

27/07/2026

Phase III

A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Master Protocol to Evaluate the Efficacy and Safety of Elecoglipron in Participants with Obesity or Overweight with or without Type 2 Diabetes Mellitus (Embold)

2025-524688-19-00Participants Living with Obesity or Overweight with at leas…

AstraZeneca AB

Nutritional and Metabolic Diseases

Spain, Germany, Italy, Poland

27/07/2026

Phase III

An Open-Label, Randomized, Multicenter Phase 3 Study Investigating the Efficacy and Safety of BGB-43395 Plus Letrozole versus CDK4/6 Inhibitors (Abemaciclib, Palbociclib, Ribociclib) Plus Letrozole in Patients with Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Systemic Anticancer Treatment for Advanced or Metastatic Disease

2025-523960-19-00Advanced or Metastatic HR+/HER2- Breast Cancer

BeOne Medicines I GmbH

Neoplasms

Poland, Italy, Germany, France, Spain

27/07/2026

Phase II

Evaluation of the effect of botulinum toxin on refractory upper limb rest tremor in parkinsonian patients, double-blind, placebo-controlled cross-over study : TOX PARK

2026-525862-23-00parkinson disease

DrugsDysport·NaCl

Centre Hospitalier Universitaire De Toulouse

Nervous System Diseases

France

24/07/2026

Phase II

DECREASE-IPC 2025-068 : De-Ecalating neoadjuvant Chemoimmunotherapy in early triple-negative BREASt cancer

2025-525040-18-00triple‑negative breast cancer

DrugsEndoxan·Paclitaxel·Pembrolizumab

Institut Paoli Calmettes

Neoplasms

France

24/07/2026

Phase II

functional imaging of digital osteoarthritis and rheumatoid arthritis using 99mTc-NTP15-5 in nuclear medicine : phase II clinical study

2025-523650-14-00Arthritis rheumatoid and finger osteoarthritis

Centre Jean Perrin

Not possible to specify

France

24/07/2026

Phase IV

VATS or Intrapleural Enzymatic Therapy for patientS with empyema (the VIETS trial)

2026-526289-25-00Parapneumonic pleural infection/pleural empyema

DrugsDornase Alfa·Alteplase

Amsterdam UMC Stichting

Therapeutics

Netherlands

24/07/2026

Phase I

Immune Cell Therapy for People with Early, Active Multiple Sclerosis

2025-522409-39-00Newly diagnosed highly-active Multiple Sclerosis

Medizinische Hochschule Hannover

Nervous System Diseases

Germany

24/07/2026

Phase III

An Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Salanersen (BIIB115) in Participants Aged 15-60 Years With Spinal Muscular Atrophy Who Are Either Treatment-Naïve or Have Previously Been Treated With Risdiplam

2025-524054-34-00Spinal Muscular Atrophy

DrugSalanersen

Biogen Idec Research Limited

Nervous System Diseases

Finland, Spain, Italy, Poland, Ireland, Germany, France

24/07/2026

Phase II

A randomised active-controlled trial to assess the safety and pharmacodynamics of two blinded doses of vortosiran and open-label apixaban in patients with non-valvular atrial fibrillation

2026-525417-31-00non-valvular atrial fibrillation

DrugsRBD4059·Apixaban

Ribocure Pharmaceuticals AB

Cardiovascular Diseases

Norway, Denmark, Poland, Sweden

24/07/2026

Phase III

A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Renal Outcomes and Mortality in Participants with Chronic Kidney Disease (Elevate-CKD)

2025-523994-41-00Chronic kidney disease (CKD) in adults, with specified rang…

DrugsElecoglipron·Dapagliflozin

AstraZeneca AB

Cardiovascular Diseases

Czechia, Italy, Hungary, Romania, Bulgaria, Sweden, Denmark, Poland, Spain, Norway, Finland, Greece, France, Germany

24/07/2026

Phase III

Phase 3 Randomized Study of Teclistamab and Talquetamab (Tec-Tal) Versus Daratumumab and Lenalidomide (DR) in Minimal Residual Disease (MRD) Positive Patients With Newly Diagnosed Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation (TiTan)

2025-525097-11-00Multiple myeloma

DrugsTalquetamab·Teclistamab·Daratumumab·Lenalidomide

Polish Myeloma Consortium

Hemic and Lymphatic Diseases

Poland

23/07/2026

Phase I

A Study to Evaluate the Safety and Activity of an Inhaled Investigational Drug (RO7616605) in Healthy Volunteers and Participants With COPD

2025-525042-22-00Chronic Obstructive Pulmonary Disease (COPD) and Chronic Br…

Genentech Inc.

Respiratory Tract Diseases

Germany

23/07/2026

Phase II

Immune dynamics and biomarkers of anti-tumor response in BMS-986340 (anti-CCR8) and nivolumab (anti-PD-1) co-treatment of metastatic tumors

2025-524125-40-01Metastatic solid tumors, with the following specific indica…

DrugNivolumab

Humanitas Mirasole S.p.A., Fondazione Humanitas Per La Ricerca Ets

Neoplasms

Italy

23/07/2026

Phase II

A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of SIR9900 in Patients with VEXAS Syndrome (SIVEX)

2025-524918-28-00VEXAS Syndrome

Sironax USA Inc.

Immune System Diseases

Italy

23/07/2026

Phase II

IKF-099/D-FLOT-TNT Total Neoadjuvant Treatment with preoperative FLOT/Durvalumab plus postoperative Durvalumab for Resectable Gastroesophageal Adenocarcinoma

2026-525185-21-00Gastroesophageal Adenocarcinoma

Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Digestive System Diseases

Germany, Spain

23/07/2026

Phase III

A Phase 3b, Open-Label Study of Crinecerfont to Evaluate Androgen Reduction and Related Outcomes in Adults With Classic Congenital Adrenal Hyperplasia

2025-524282-24-00Classic Congenital Adrenal Hyperplasia (CAH)

DrugCrinecerfont

Neurocrine Biosciences Inc.

Hormonal diseases

Czechia, Germany, Sweden, Portugal, Romania, Bulgaria, Italy, Austria, Spain

23/07/2026

Phase III

Prospective, multicentre, open-label, single arm trial on contraceptive efficacy, safety and tolerability of LPRI-CF113 (Drospirenone 4 mg + 2.8 mg) during 13 cycles.

2026-525727-24-00No medical condition

Chemo Research S.L.

Not possible to specify

Sweden, Czechia, Spain, Hungary, Poland, Finland, Romania

23/07/2026

Phase III

A Phase 2/3 Randomized, Double Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants with Huntington’s Disease

2025-522263-14-00Huntington’s Disease

DrugSKY-0515

Skyhawk Therapeutics Inc.

Nervous System Diseases

Germany, Spain

23/07/2026

Phase I/II

A Phase 1/2, dose escalation and expansion study of TRI-611, an oral ALK molecular glue degrader in participants with advanced ALK-positive NSCLC

2025-524418-27-00Advanced ALK-positive NSCLC

Triana Biomedicines Inc.

Respiratory Tract Diseases

France, Italy, Germany, Spain

22/07/2026

Phase I

An unblinded, single arm, pilot observational study to test the safety, tolerability, immunogenicity and the biological effects of TRB-001 vaccination in individuals who have previously undergone aSyn immunotherapy

2026-526294-42-00Parkinson's disease

Tridem Bioscience FlexCo

Nervous System Diseases

Austria

22/07/2026

Phase IV

Real-World Effectiveness of the Adjuvanted RSVPreF3 Vaccine in Adults ≥60 Years: A Pragmatic Randomized Trial (BronquiVal)

2026-526804-59-00Respiratory syncytial virus infection–related respiratory d…

Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana

Respiratory Tract Diseases

Spain

22/07/2026

Phase III

Colchicine for the Reduction of Dependency and Vascular Events after an Acute Intracerebral Hemorrhage (CoVasc-ICH2)

2025-523435-18-00Major cardiovascular events (MACE), spontaneous intracerebr…

Hamilton Health Sciences Corporation, PHRI Population Health Research Institute International

Cardiovascular Diseases

Spain, Belgium

22/07/2026

Phase IV

Do GLP-1 based therapies improve the immunological response to vaccination in diabetes?

2026-525909-13-00Diabetes

DrugsPneumococcal Vaccine·Liraglutide

Radboud universitair medisch centrum Stichting

Immune System Diseases

Netherlands

22/07/2026

Phase II

Local and systemic immune modulation by Rilvegostomig (AZD2936) in the treatment of advanced gastric cancer (RILVE Project)

2026-525620-23-00advanced gastric cancer

DrugsRilvegostomig·Pembrolizumab

Vall D Hebron Institute Of Oncology

Neoplasms

Spain

22/07/2026

Phase I

Tarlatamab Before and After Surgery for Recurrent High-Grade Glioma

2025-524359-30-00surgically resectable recurrent high-grade glioma

Vall D Hebron Institute Of Oncology

Neoplasms

Spain

22/07/2026

Phase I/II

A Phase 1/2a, Open-label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of BMS-986528 in Participants with Refractory Rheumatoid Arthritis

2025-520666-22-00Refractory, difficult-to-treat Rheumatoid Arthritis

DrugTocilizumab

Bristol-Myers Squibb Services Unlimited Company

Immune System Diseases

Poland, Italy, Spain, Germany

22/07/2026

Phase III

A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared with Oral Semaglutide in Adults with Type 2 Diabetes Mellitus (Eluminate-2)

2025-523933-24-00type 2 diabetes mellitus

AstraZeneca AB

Nutritional and Metabolic Diseases

Poland, Hungary, Italy, Bulgaria, Germany

22/07/2026

Phase II

A Phase 2, Multicenter, Randomized, Double-blind, Placebocontrolled Study, to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Intrathecally Administered Mivelsiran in Adult Participants with Early-Stage Down Syndrome-Associated Alzheimer’s Disease (DS-AD)

2025-523390-42-00Early-Stage Down Syndrome-Associated Alzheimer’s Disease (D…

DrugMivelsiran

Alnylam Pharmaceuticals Inc.

Nervous System Diseases

Italy, Netherlands, Spain, Germany, Ireland

22/07/2026

Phase I

Phase 1/1b Study of BMS-986463 in Advanced Malignant Tumors

2025-523067-38-01Advanced Malignant Tumors; High-grade Serous Ovarian Carcin…

Bristol-Myers Squibb Services Unlimited Company

Neoplasms

Spain, France, Italy

21/07/2026

Phase III

A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elafibranor in Adult Participants with Primary Sclerosing Cholangitis

2026-525242-29-00Primary Sclerosing Cholangitis

Ipsen Bioscience Inc.

Digestive System Diseases

Spain, Sweden, Germany, Romania, Finland, Portugal, Austria, Italy, Denmark, Czechia, France, Netherlands, Poland, Belgium, Norway

21/07/2026

Phase II

Randomized Controlled Trial Assessing the Effectiveness and Safety of Fecal Microbiota Transfer for VRE Eradication in Immunocompromised Patients (EU CTR, Phase II) – VRE-ex

2026-525632-41-00Intestinal colonization with vancomycin-resistant enterococ…

Fraunhofer Institute For Translational Medicine And Pharmacology ITMP

Bacterial Infections and Mycoses

Germany

21/07/2026

Phase I/II

A Phase 1/2 First-Time-in-Human, open-label, multicenter, dose escalation and dose optimization study of GSK5471713 in adult participants with metastatic castration resistant prostate cancer (mCRPC).

2025-523874-17-00Neoplasms, Prostate

Glaxosmithkline Research & Development Limited

Neoplasms

Netherlands, France, Spain

21/07/2026

Phase I

A more sustainable perioperative treatment regimen for gastroesophageal cancer —replacing 5-FU with capecitabine within the FLOT regimen

2026-526209-13-00Gastric Cancer, Esophageal cancer

DrugCapecitabine

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Neoplasms

Netherlands

21/07/2026

Phase II

A Phase 2, open-label, randomized, dose optimization study evaluating the efficacy and safety of belantamab mafodotin administered in combination with cyclophosphamide, bortezomib, and dexamethasone in adult participants with newly diagnosed amyloid light chain amyloidosis (ALANIS)

2025-522803-60-00newly diagnosed amyloid light chain amyloidosis

DrugsEndoxan·Velcade·Bortezomib

Glaxosmithkline Research & Development Limited

Immune System Diseases

Italy, Greece, Spain

21/07/2026

Phase III

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to a Regimen of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination with Capsid Inhibitor Lenacapavir Twice Yearly in Virologically Suppressed Adults with HIV-1 Infection on Stable Oral Treatment Regimens

2025-524336-19-00HIV-1

DrugsCobicistat·Doravirine·Ritonavir·Tenofovir DF

Gilead Sciences Inc.

Virus Diseases

Poland, Italy, France, Spain, Germany, Netherlands

21/07/2026

Phase III

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to Long-acting Antiretroviral Therapy of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination With the Capsid Inhibitor Lenacapavir Twice-Yearly Versus Cabotegravir and Rilpivirine Every 8 Weeks in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

2025-524335-39-00HIV-1

DrugsTeropavimab·Zinlirvimab·Rilpivirine·Cabotegravir

Gilead Sciences Inc.

Virus Diseases

Netherlands, Poland, Germany, France, Spain, Italy

21/07/2026

Phase III

A Phase 3, Double-blinded, Vehicle-controlled Trial to Investigate the Efficacy and Safety of Twice-daily Delgocitinib Cream in Adult Participants with Lichen Sclerosus During a 12-Week Initial Treatment Period Followed by a 40-Week Continuation Treatment Period

2025-524873-17-00Lichen Sclerosus

DrugDelgocitinib

Leo Pharma A/S

Skin and Connective Tissue Diseases

Italy, France, Spain, Poland, Germany

21/07/2026

Phase II

J2J-MC-JZLL - preEMBER: A Phase 2, Open-label Study Evaluating Imlunestrant in Premenopausal Women with Estrogen Receptor-Positive, HER2-Negative Breast Cancer.

2025-523258-15-00Breast Neoplasms

DrugsGoserelin·Tamoxifen

Eli Lilly & Co.

Neoplasms

Belgium, France, Italy, Germany, Ireland

21/07/2026

Phase II

DOXYCYCLINE PENETRATION INTO BONE AND JOINT.

2025-524744-36-00Patients requiring total hip arthroplasty for coxofemoral o…

DrugDoxycycline

Centre Hospitalier Universitaire De Caen Normandie

Bacterial Infections and Mycoses

France

20/07/2026

Phase I

Study of MX006 in Patients With Advanced and/or Metastatic Tumors known to express B7-H3

2025-524929-41-00Advanced Solid Tumor Types Known to Express B7-H3

Myricx Pharma Limited

Neoplasms

Spain

20/07/2026

Phase II

Randomized Phase II study of multi-peptide vaccination and bispecific PSMAxCD3 antibody treatment in patients with biochemical relapse of prostate cancer

2025-522144-41-00biochemical relapse of prostate cancer

Universitaetsklinikum Tuebingen AöR

Male Urogenital Diseases

Germany

20/07/2026

Phase II

HOVON 180 CLL: Prospective phase II trial of pirtobrutinib treatment (24 cycles) with 12 cycles of epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. ODYSSEUS study (Outcome-Driven trial for relapsed CLL/SLL combining BTK and bispecific antibodY to improve outcome)

2025-524842-89-00chronic lymphocytic leukemia (CLL) and small lymphocytic ly…

Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Hemic and Lymphatic Diseases

Netherlands

20/07/2026

Phase II

A PHASE II, SINGLE ARM, OPEN LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF CEVOSTAMAB IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED A PRIOR BCMA TARGETING CAR T-CELL THERAPY

2026-525736-42-00Multiple Myeloma (MM)

F. Hoffmann-La Roche AG

Neoplasms

Germany

20/07/2026

Phase II

A Phase IIb, randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy and safety of concomitant use of eplontersen and ALXN2220 compared with eplontersen and placebo in adult participants with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).

2025-523908-75-00Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

AstraZeneca AB

Cardiovascular Diseases

Germany, Italy, Spain, France, Sweden

20/07/2026

Phase III

A placebo-controlled comparability study to compare two presentations of cagrilintide for weight management in participants with overweight or obesity

2025-524249-29-00Participants with overweight or obesity

Novo Nordisk A/S

Nutritional and Metabolic Diseases

Sweden, Greece, Hungary, Portugal

20/07/2026

Phase III

A randomized, placebo-controlled, double-blind Phase 3 study to evaluate the efficacy, safety and tolerability of votoplam in participants with Huntington’s Disease

2025-522227-99-00Huntington’s Disease

Novartis Pharma AG

Nervous System Diseases

Norway, Poland, Spain, Sweden, Bulgaria, Netherlands, Finland, Portugal, Austria, Italy, Greece, Ireland, Czechia, France, Romania, Belgium, Germany, Denmark, Slovakia, Hungary

20/07/2026

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

2025-524711-36-00Narcolepsy Type 1

DrugALKS 2680

Alkermes Inc.

Nervous System Diseases

Sweden, Finland, Belgium, Spain, Austria, Netherlands, France, Norway, Germany, Italy, Poland

20/07/2026

Phase II

A Phase 2a, multi centric, open label clinical study to explore the safety and tolerability, the pharmacokinetics and pharmacodynamics profile and first signs of efficacy of PTI5803 administered as adjunctive therapy with a 3-dose escalation regimen in patients >= 14 years of age with drug-resistant seizures associated to focal cortical dysplasia, followed by an optional open-label extension study.

2026-525162-21-00Drug resistant seizures associated to Focal Cortical Dyspla…

DrugPTI5803

PannTheraPi

Nervous System Diseases

France

20/07/2026

Phase III

Phase 3 Single-Arm Open-Label Study to Evaluate the Efficacy and Safety of Zodasiran in Adolescent Subjects (age 12 to <18 years) with Homozygous Familial Hypercholesterolemia (SPRUCE)

2025-523662-24-00Homozygous Familial Hypercholesterolemia (HoFH)

DrugZodasiran

Arrowhead Pharmaceuticals Inc.

Cardiovascular Diseases

Netherlands, Denmark, Norway, Sweden, Poland

20/07/2026

Phase I

A study comparing the new drugs PG511/PG521/PG531 produced by Celon Pharma SA with the drug PG203 in healthy volunteers.

2025-524936-20-00Treatment of psychotic disorders like schizophrenia Treatme…

Celon Pharma S.A.

Mental Disorders

Poland

20/07/2026

Phase II

An open label multicenter phase II study to investigate the efficacy, safety and tolerability of the Obe-cel in patients with minimal residual disease (MRD) of Philadelphia negative (Ph neg) B-precursor acute lymphoblastic leukaemia (B-ALL) - GMALL-OBECEL

2025-524169-26-00Ph-negative CD19 positive B-precursor ALL patients in CR1 w…

DrugAUTO1

Goethe University Frankfurt

Hemic and Lymphatic Diseases

Germany

20/07/2026

Phase I/II

A phase I/IIa safety, dose finding and feasibility trial of CD30/CEA CART in patients with liver metastases from CEA positive colorectal adenocarcinoma

2026-526225-18-00Colorectal Adenocarcinoma

Universitaetsklinikum Regensburg AöR

Neoplasms

Germany

20/07/2026

Phase III

Intrathecal Administration of MELPIDA For Hereditary Spastic Paraplegia Type 50 (SPG50): A multicenter Phase 3, Open-Label Trial with Matched Prospective Concurrent Control Arm (CT-MEL-03)

2025-524576-28-00Hereditary Spastic Paraplegia Type 50 (SPG50)

DrugsMelpida·Diphenhydramine·Paracetamol·Sirolimus

Elpida Therapeutics SPC

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Spain

17/07/2026

Phase II

SETRAPED : A prospective, multicenter study evaluating the efficacy and tolerance of transmucosal midazolam for proportionate palliative sedation in children with refractory symptoms

2025-523840-11-00Children with refractory symptoms

DrugMidazolam

Centre Leon Berard

Pathological Conditions, Signs and Symptoms

France

17/07/2026

Phase III

Triple oral therapy with bempedoic acid vs usual care in early lipid management of patients with acute coronary syndrome

2026-525740-15-00Acute Coronary Syndrome

Fondazione Per Il Tuo Cuore Onlus Denominabile Anche Fondazione Italiana Per La Lotta Alle Malattie Cardiovascolari Onlus Ed Anche Heart Care Foundation Hcf Onlus

Cardiovascular Diseases

Italy

17/07/2026

Phase I

Bioequivalence study of Vitamin D3 Pharma Patent 20,000 IU and the Vigantol 20,000 IU oral drops solutions and assessment of bioavailability in healthy volunteers

2026-526224-48-02Healthy volunteers

Pharma Patent Kft.

Not possible to specify

Hungary

17/07/2026

Phase I

A single center, randomized, controlled trial in healthy volunteers using dermal open flow microperfusion to assess cutaneous BE of two doxepin hydrochloride creams

2026-526078-18-00No medical condition is being investigated in this clinical…

Medical University Of Graz

Not possible to specify

Austria

17/07/2026

Phase I

A Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of IMC-S118AI in HLA-A*02:01-Positive Participants With Type 1 Diabetes

2025-524449-28-00Type 1 Diabetes

Immunocore Limited

Nutritional and Metabolic Diseases

Austria

17/07/2026

Phase II

An Open-Label Study to Assess the Hemodynamic Effect and the Safety of TX000045 After 16 Weeks of Treatment in Participants With Pulmonary Hypertension due to Interstitial Lung Disease

2026-525810-80-00Pulmonary hypertension secondary to interstitial lung disea…

Tectonic Operating Company Inc.

Cardiovascular Diseases

Poland, Romania, Spain

17/07/2026

Phase I

Bioequivalence clinical trial of two formulations of dapagliflozin/metformin

2026-527164-32-00Healthy participants

Laboratorios Alter S.A.

Nutritional and Metabolic Diseases

Spain

17/07/2026

Phase II

Tolerability and efficacy of treating locally advanced Resectable Oral Cancer with neoadjuvant INtratumoral anti-CTLA4 ImmunoTherapy combined with systemic anti-PD-1 (ROCinIT).

2025-523617-29-01Oral cavity squamous cell carcinoma

DrugsIpilimumab·Nivolumab

Amsterdam UMC Stichting

Neoplasms

Netherlands

17/07/2026

Phase III

Paracervical block with ropivacaine for pain relief in second trimester medical abortion - a double blind placebo controlled randomized trial

2025-524599-52-03abortion

DrugRopivacaine

Karolinska Institutet

Female Urogenital Diseases and Pregnancy Complications

Sweden

17/07/2026

Phase III

FOSFORMEN : Randomized, multicenter, non-inferiority trial comparing the efficacy of fosfomycin versus fluoroquinolones or cotrimoxazole as oral follow-up treatment in febrile urinary tract infections in men caused by susceptible enterobacteria

2026-525972-25-00Febrile male urinary tract infections caused by Escherichia…

DrugsFosfomycin·Ciprofloxacin·Levofloxacin

Assistance Publique Hopitaux De Paris

Male Urogenital Diseases

France

16/07/2026

Phase II

PITALC. Pilot study on the effect of PITAC (Pressurized IntraThoracic Aerosol Chemotherapy) by videothoracoscopy in patients with malignant pleural effusion in the light of the results of a retrospective historical cohort treated with talc pleurodesis by videothoracoscopy

2025-523482-23-00neoplastic pleural effusion

Hospices Civils De Lyon

Neoplasms

France

16/07/2026

Phase III

PROPHY-SEIN - Evaluation of the effect of antibiotic prophylaxis during lumpectomy for breast cancer: prospective randomised double-blind noninferiority study of placebo vs cefazolin

2025-525020-99-00Breast Cancer

University Hospital Of Clermont-Ferrand

Not possible to specify

France

16/07/2026

Phase II

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Confirm Efficacy and Safety of MH002 and to Assess the Effect of Dose in Patients With Mild-to-Moderate Ulcerative Colitis Insufficiently Controlled With 5-Aminosalicylic Acid

2025-524682-24-00Ulcerative Colitis

Microbial Resource Management Health

Digestive System Diseases

Czechia, Poland, Italy

16/07/2026

Phase I

A double-blind, randomised, placebo-controlled first-in-human/Phase Ib trial to investigate safety, tolerability, pharmacokinetics, and preliminary efficacy of single and multiple doses of TIR-C 2% cutaneous emulsion in adults with mild to moderate atopic dermatitis

2026-526343-35-00Atopic dermatitis

Pharmability AB

Skin and Connective Tissue Diseases

Sweden

16/07/2026

Phase II

Randomized, observer-blind, placebo-controlled, four Parallel Group, Clinical Trial for exploring the Efficacy and Tolerability of two different strengths ketotifen nasal spray (Ketotifen 0.025 mcg/ml and 0.050 mcg/ml) vs sodium cromoglicate nasal spray 2% in Patients with Rhinitis

2026-525419-16-00Rhinitis

Eudemus Pharmaceuticals Limited

Otorhinolaryngologic Diseases

Greece

16/07/2026

Phase II

Obinutuzumab for systemic lupus erythematosus pure membranous nephropathy: a phase II trial (OBLUMEN)

2024-519985-35-00systemic lupus erythematosus pure membranous nephropathy

DrugObinutuzumab

Assistance Publique Hopitaux De Paris

Pathological Conditions, Signs and Symptoms

France

15/07/2026

Phase II

COLOVERT – Conversion therapy in colorectal cancer with peritoneal metastases not amenable to upfront cytoreductive surgery and HIPEC: a phase II “pick-the-winner” open-label randomized trial

2026-526122-41-00Colorectal cancer with peritoneal metastases

DrugsMitomycin C·Doxorubicin·Irinotecan·Oxaliplatin

Uppsala University Hospital

Not possible to specify

Sweden

15/07/2026

Phase I/II

Phase I/II clinical trial on the use of central nervous system administrations of CART-NKG2D or NKIL15 cells in children, adolescent and young adults with recurrent/refractory high grade Central Nervous System tumours (CINK-CAR)

2026-525876-24-00Central nervous system tumours

Hospital Universitario La Paz

Neoplasms

Spain

15/07/2026

Phase III

The MODIFY Study: A Phase 3b/4 randomized, double-blind, placebo-controlled, multicentre study evaluating the impact of early intervention with depemokimab on exacerbation rate, clinical remission, lung function decline, and safety in adults and adolescents with at risk Type 2 asthma, conducted up to 156 weeks.

2025-524463-20-00Asthma

DrugsDopamine·Depemokimab

Glaxosmithkline Research & Development Limited

Respiratory Tract Diseases

Ireland, Spain, Germany, Czechia, Bulgaria, France, Belgium, Romania, Italy

14/07/2026

Phase II

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-755 in Acute Ischemic Stroke

2025-522734-31-00Acute Ischemic Stroke

Takeda Development Center Americas Inc.

Nervous System Diseases

Greece, Belgium, France, Germany

14/07/2026

Phase IV

Early TRIPLE versus dual LIPID lowering treatment in peOple with atherosclerotic cardiovascular disease and hypercholesterolemia Undergoing elecTive revascularisation - The randomized, controlled, open-label, parallel group TRIPLE-LIPID-OUT trial

2026-525917-29-00Peripheral arterial disease, Coronary artery atheroscleroti…

Medical University Of Graz

Cardiovascular Diseases

Germany, Austria

14/07/2026

Phase III

A Randomized, Open Label, 3-arm Phase 3 Study of Precemtabart Tocentecan with or Without Bevacizumab Compared to Trifluridine/Tipiracil plus Bevacizumab in Participants with Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

2025-524648-37-00Metastatic colorectal cancer

Merck Healthcare KGaA

Neoplasms

Belgium, Germany, France, Denmark, Poland, Spain, Netherlands, Italy, Austria

14/07/2026

Phase I/II

FLAsH-IV-AML: A phase I/II multi-center study to assess the tolerability and efficacy of the addition of hydroxyurea to salvage treatment with fludarabine, ara-C, idarubicin and venetoclax for adults with relapsed or refractory acute myeloid leukemia

2026-526961-76-00Adults (≥ 18 years of age) with relapsed or refractory acut…

DrugsIdarubicin·Cytarabine·Fludarabine·Venetoclax

Karolinska University Hospital

Hemic and Lymphatic Diseases

Sweden

14/07/2026

Phase II

A Phase II, Open-Label, Single-Arm, Multicentre Study of Immunotherapy and non-invasive response evaluation in cutaneous squamous cell carcinoma as an organ preservation strategy: a proof of concept clinical study and translational correlates - INCEPT

2025-523633-25-00cutaneous squamous cell carcinoma

DrugCemiplimab

Fondazione GONO Plus

Neoplasms

Italy

14/07/2026

Phase III

A Sequential Phase 2/3, Single-Arm, Open-Label Study in Adults Followed by a Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults and Adolescents with Focal Segmental Glomerulosclerosis

2025-524448-36-00Focal segmental glomerulosclerosis (FSGS)

DrugPegcetacoplan

Apellis Pharmaceuticals Inc.

Female Urogenital Diseases and Pregnancy Complications

France, Portugal, Spain, Slovakia, Italy, Germany, Poland

14/07/2026

Phase III

RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients with Metastatic Pancreatic Adenocarcinoma

2025-525088-34-00Metastatic Pancreatic Adenocarcinoma

Revolution Medicines Inc.

Digestive System Diseases

Poland, Belgium, Norway, Sweden, Austria, Germany, Denmark, Netherlands, France, Italy, Spain

14/07/2026

Phase I

An open-label, multicentric, phase 1 study to evaluate the safety, tolerability, and radiation dosimetry of endogenous radioligand therapy with (¹⁷⁷Lu)Lutetiumvipivotidtetraxetan in women with metastatic triple negative breast cancer (TNBC)

2025-524027-49-00Metastatic triple negative breast cancer

Universitaetsklinikum Aachen AöR

Not possible to specify

Germany

14/07/2026

Phase IV

Efficacy of oral bicarbonate versus placebo on the risk of assisted delivery in nulliparous women with prolonged labour (ProLabour): protocol fora randomized controlled trial

2026-525682-45-00Prolonged labour

Region Hovedstaden

Female Urogenital Diseases and Pregnancy Complications

Denmark

14/07/2026

Phase II

A Phase 2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Surovatamig in Adults with Antibody-mediated Kidney Disease

2025-524139-38-00Antibody-mediated Kidney Disease

DrugSurovatamig

AstraZeneca AB

Immune System Diseases

France, Germany, Italy, Belgium, Poland, Spain

13/07/2026

Phase III

Model-informed precision dosing for linezolid: a randomized clinical trial

2024-517888-23-00Bacterial infection (pneumonia, skin or soft tissue infecti…

DrugLinezolid

University Medical Center Hamburg-Eppendorf

Bacterial Infections and Mycoses

Germany

13/07/2026

Phase II

Phase II, Multicenter, Randomized Study to Evaluate Safety and Efficacy of MRD-guided Therapy with Reduced versus Standard Dose of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (REBEL)

2025-525096-83-00Relapsed/refractory Multiple myeloma

DrugPomalidomide

Polish Myeloma Consortium

Hemic and Lymphatic Diseases

Poland

13/07/2026

Phase I/II

A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor Surzetoclax (ABBV-453) given as Monotherapy or in Combination with Antimyeloma Regimens in Subjects with Multiple Myeloma

2025-525105-20-00Multiple Myeloma (MM), Multiple Myeloma (MM)

DrugEtentamig

AbbVie Deutschland GmbH & Co. KG

Neoplasms

Germany, Poland, Czechia, Belgium, France, Greece, Sweden, Portugal, Italy

13/07/2026

Phase II

Inducing durable immunological control of HIV-1 through administration of long-acting broadly neutralizing antibodies and low-dose anti-PD-1 – a randomized, double-blinded, placebo-controlled trial (the IDUNN trial)

2025-523725-17-00HIV-1 disease

DrugsTeropavimab·Zinlirvimab·Nivolumab

Region Midtjylland

Immune System Diseases

Sweden, Norway, Denmark, Iceland

13/07/2026

Phase II

A Phase 1b-2, Multicenter, Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of REC-4881 in Patients with Familial Adenomatous Polyposis (FAP)

2026-525282-50-00Familial Adenomatous Polyposis

Recursion Pharmaceuticals Inc.

Neoplasms

Netherlands, Germany, Spain

13/07/2026

Phase II

SUNCET: Low sodium oxybate Use for Nocturnal Cluster headache: safety, Efficacy and Tolerability of XYWAV - a Phase 2 Randomized, Double-Blind, Placebo-Controlled, bi-center Study

2025-523293-17-00Cluster headache

Leids Universitair Medisch Centrum (LUMC)

Nervous System Diseases

Netherlands

13/07/2026

Phase IV

Phase IV randomized, single-blind clinical trial with three parallel arms to compare ovulation triggering strategies in IVF cycles with fresh embryo transfer.

2026-526292-37-01Women with infertility and low ovarian reserve.

DrugFollitropin delta

Instituto De Investigacion Sanitaria Fundacion Para La Investigacion Del Hospital Clinico De Valencia-INCLIVA

Reproductive and Urinary Physiological Phenomena

Spain

13/07/2026

Phase I

A Phase 1, First-in-human, Dose Escalation Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies

2026-525234-39-00Relapsed or Refractory higher-risk myelodysplastic syndrome…

Janssen Cilag International

Neoplasms

France, Spain, Germany, Denmark, Belgium

13/07/2026

Phase II

Achieving viral CLEARance in immunocompromised participants with long-term persistence of SARS-CoV-2 - an open-label randomized trial (CLEAR)

2025-524442-10-00Long-term persistence of SARS-CoV-2

DrugsPaxlovid·Remdesivir

Goethe University Frankfurt

Virus Diseases

Germany, Spain

13/07/2026

Phase III

Effect of Vitamin D supplementation on MyocardIal Fibrosis in PaTients with Acute Myocarditis (EDIT-AM): a multicenter, open-label, randomized controlled trial

2025-523092-33-00Myocardial fibrosis, Acute myocarditis

Spanish Society Of Cardiology

Cardiovascular Diseases

Spain

10/07/2026

Phase I

A Randomized, Placebo-controlled, Double-blind, Dose-finding Phase 1b Study to Assess the Safety, Immunogenicity and Pharmacodynamics of TRB-001 in Early Idiopathic Parkinson’s Disease Patients

2024-519123-14-00Parkinson's disease

Tridem Bioscience FlexCo

Nervous System Diseases

Austria, Germany

10/07/2026

Phase II

Prospective trial of [18F]AlF-FAPI-74 for PET imaging of fibroblast activation protein in patients with endometriosis

2026-525272-25-00endometriosis

UZ Leuven

Female Urogenital Diseases and Pregnancy Complications

Belgium

10/07/2026

Phase I

A Phase 1, Randomized, Placebo-Controlled, Multiple-Dose, Dose-Ranging Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CTX611 in Healthy Adult Participants

2026-526708-56-00Thromboembolic disorders

CRISPR Therapeutics AG

Cardiovascular Diseases

Hungary

10/07/2026

Phase I/II

EXUROC Bladder Target - A phase Ib/ll study to determine the safety, tolerability, and efficacy of LP-184 treatment in patients with advanced/metastatic urothelial carcinoma

2026-525808-94-00Oncology

Region Hovedstaden

Neoplasms

Denmark

10/07/2026

Phase I

A study to learn how a high-fat meal affects the way elinzanetant is taken up by the body in healthy women

2026-525569-30-00Vasomotor symptoms as a sex hormone-dependent disorder in w…

Bayer AG

Hormonal diseases

Germany

10/07/2026

Phase III

Preventing urinary tract infections in infants and young children with probiotic E. coli Nissle: FinNissle randomized controlled trial

2026-526444-13-01Urinary tract infection or Pyelonephritis

Pohjois-Pohjanmaan hyvinvointialue

Bacterial Infections and Mycoses

Finland

10/07/2026

Phase II

A Phase 2, Open-Label, Single-Arm Study of Lirafugratinib in Patients With Previously Treated, Unresectable, Locally Advanced or Metastatic Solid Tumors (Excluding Cholangiocarcinoma) With FGFR2 Fusion or Rearrangement

2025-523923-22-00Previously Treated, Unresectable, Locally Advanced or Metas…

Elevar Therapeutics Inc.

Neoplasms

France, Spain

09/07/2026

Phase III

AIEOP-BFM ALL 2025 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia

2025-522190-11-01acute lymphoblastic leukemia in children and adolescents

DrugsAsparaginase Erwinia chrysanthemi·Pegaspargase·Mercaptopurine·Blinatumomab

Universitaetsklinikum Schleswig-Holstein AöR

Neoplasms

Germany

09/07/2026

Phase II

Giving Upfront Anti-p40 to Reduce toxicity from Dual Immune Checkpoint Inhibition in MESOthelioma

2026-526036-38-00Pleural mesothelioma

DrugUstekinumab

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Neoplasms

Netherlands

09/07/2026

Phase IV

Early switch to oral antibiotic therapy in vertebral osteomyelitis: a multicentre, open-label, randomised, active control, parallel group, non-inferiority trial (sWITCH-VO)

2026-526270-17-00bone and joint infections

University Of Cologne

Musculoskeletal Diseases

Germany

09/07/2026

Phase II

Master Protocol Full Title- A Master Protocol for an Exploratory, Phase 2a, Proof-of-Concept Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis. ISA 2 to Master Protocol ARGX-999-2-MG-2000 – an Exploratory, Phase 2a, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis

2025-522939-33-00AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthe…

DrugEmpasiprubart

Argenx

Immune System Diseases

Greece, Italy, Germany, Belgium, Netherlands, Spain, Poland

08/07/2026

Phase II

Open-label, single-center, single-arm phase 2 futility trial evaluating the oral indapamide for reducing progression of disability in people with primary and secondary progressive multiple sclerosis (MS)

2026-525260-18-00Multiple Sclerosis

DrugIndapamide

Amsterdam UMC Stichting

Nervous System Diseases

Netherlands

08/07/2026

Phase III

A multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Immunotherapy (Beltavac®) with Polymerized Allergenic Extract of a Mixture of Dermatophagoides and Blomia tropicalis in Patients with Allergic Rhinitis/rhinoconjunctivitis.

2026-526105-15-00Allergic rhinitis/rhinoconjunctivitis due to house dust mit…

Probelte Pharma S.L.

Eye Diseases

Spain

08/07/2026

Phase I

Nasal application of Staphylococcus lugdunensis for decolonization of Staphylococcus aureus – a first-in-human proof-of-concept microbiome intervention study

2024-514894-22-01Persistent or intermitting colonization of the nose with St…

Universitaetsklinikum Tuebingen AöR

Bacterial Infections and Mycoses

Germany

08/07/2026

Phase III

Fight Osteosarcoma Through European Research evolving study platform from diagnosis to relapse (FOSTER evolving study platform)

2023-505575-69-01Osteosarcoma

DrugCabozantinib

Institut Gustave Roussy

Neoplasms

Sweden, Poland, Denmark, Finland, Netherlands, Italy, France, Spain

08/07/2026

Phase II

A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of E2086 in Adults with Narcolepsy

2025-523503-30-00Narcolepsy

Eisai Limited

Nervous System Diseases

Belgium, Italy, Spain, Germany

08/07/2026

Phase II

HMBeacon: A Phase 2, Randomized, Double-blind Study of the Safety, Tolerability, Efficacy, and Pharmacodynamics of Multiple Dose ALN-6400 in Female Patients with Von Willebrand Disease (VWD) and Heavy Menstrual Bleeding (HMB)

2025-524967-19-00Von Willebrand Disease (VWD) and Heavy Menstrual Bleeding (…

Alnylam Pharmaceuticals Inc.

Cardiovascular Diseases

Netherlands, Sweden, Germany

08/07/2026

Phase I

A study to compare how 2 different formulations of survodutide are taken up in the body when given by injection in healthy men and women with and without overweight or obesity

2026-526307-30-00Healthy

Boehringer Ingelheim International GmbH

Not possible to specify

Germany

08/07/2026

Phase I

A Trial to Evaluate the Safety and Drug Levels of Single and Multiple Oral Doses of AT-587 in Healthy Adults

2026-526237-26-00Chronic hepatitis E virus (HEV) infection

Atea Pharmaceuticals Inc.

Virus Diseases

Belgium

07/07/2026

Phase I

A clinical trial comparing how the body takes up budesonide from different forms of medicine when taken by mouth with or without food.

2025-522686-29-00Acute eosinophilic esophagitis

Dr. Falk Pharma GmbH

Digestive System Diseases

Sweden

07/07/2026

Phase I

Phase I Safety and Immunogenicity Study of a Multivalent Gonorrhoea Vaccine

2026-526168-19-00Gonorrhea

LimmaTech Biologics AG

Bacterial Infections and Mycoses

Germany

07/07/2026

Phase II

A Phase 2 Open-Label, Multi-Center Study of BMS-986504 as Monotherapy and in Combination with Other Agents in Participants with Advanced and/or Metastatic Solid Tumors with Homozygous MTAP Deletion

2025-524285-18-00Advanced and/or Metastatic Solid Tumors with Homozygous MTA…

Bristol-Myers Squibb Services Unlimited Company

Neoplasms

Belgium, Ireland, Germany, Norway, Italy, France, Spain

07/07/2026

Phase III

An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics and Safety of Xembify versus Gamunex-C in Participants with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

2025-522165-30-00Chronic inflammatory demyelinating polyradiculoneuropathy (…

Grifols Therapeutics LLC

Nervous System Diseases

Romania, Czechia, Poland

07/07/2026

Phase III

Multicenter, randomized, double-blind, parallel-group clinical study comparing RD03/2016 (levoFloxacin and ketorolac trometAmol) eye drops vs Leviosa® (levofloxacin and dexamethaSone 21-phosphaTe) eye drops for 7 days for the prevention and treatment of inflammation and prevention of infection associated with cataract surgery in adults. (FAST 7)

2026-525594-39-00Cataract

DrugLevofloxacin

Ntc S.r.l.

Eye Diseases

Spain, Poland, Greece, Sweden, Italy

07/07/2026

Phase I

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors (FiREBOLT)

2025-521887-37-00Ovarian Neoplasms Breast Neoplasms Pancreatic Intraductal N…

Eli Lilly & Co.

Neoplasms

Germany, Netherlands

07/07/2026

Phase I/II

A PHASE 1/2 STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFECTS ON CLINICAL OUTCOMES OF PEGTIBATINASE (TVT-058) ADMINISTERED SUBCUTANEOUSLY IN SUBJECTS WITH CYSTATHIONINE BETASYNTHASE-DEFICIENT HOMOCYSTINURIA (COMPOSE)

2023-509074-31-00Classical Homocystinuria

DrugPegtibatinase

Travere Therapeutics Switzerland GmbH, Travere Therapeutics Inc.

Nutritional and Metabolic Diseases

France

07/07/2026

Phase III

C6461016 - A PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA

2025-524717-86-00LOCALLY ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JU…

Pfizer Inc.

Neoplasms

France, Spain, Italy

07/07/2026

Phase III

A study to evaluate the dose-exposure, safety, and exploratory efficacy of nerandomilast in children and adolescents from 2 years to less than 18 years of age with fibrosing interstitial lung disease (Part A: double-blind, placebo-controlled in children from 6 to less than 18 years of age and open-label active treatment in children from 2 to less than 6 years of age), followed by an open-label phase with active treatment (Part B)

2025-523369-32-00Fibrosing interstitial lung disease

DrugNerandomilast

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

Respiratory Tract Diseases

Belgium, Greece, Germany, France, Finland, Spain, Czechia, Poland, Italy, Netherlands, Denmark, Portugal

07/07/2026

Phase III

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Cevostamab in Combination with Pomalidomide and Dexamethasone Versus Standard of Care in Patients with Multiple Myeloma who Have Received One to Three Prior Lines of Therapy

2025-524028-23-00Multiple Myeloma

F. Hoffmann-La Roche AG

Neoplasms

France, Germany, Italy, Greece, Denmark, Czechia, Spain, Poland

07/07/2026

Phase III

Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan in Combination with FOLFOX Compared to Standard of Care in Subjects with First-Line Metastatic Pancreatic Ductal Adenocarcinoma - AndroMETa-PDAC-288

2025-522563-15-00Metastatic Pancreatic Ductal Adenocarcinoma; PDAC

DrugsCalcium folinate·Telisotuzumab Adizutecan·Fluorouracil·Irinotecan

AbbVie Deutschland GmbH & Co. KG

Neoplasms

Portugal, Spain, France, Italy, Germany, Austria

06/07/2026

Phase II

A Phase 2 Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety and Efficacy of MTX-474 in the Treatment of Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)

2025-523288-39-00Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Mediar Therapeutics Inc.

Immune System Diseases

Netherlands, Romania, Poland, France, Italy, Spain

06/07/2026

Phase III

TAILORswitch (PADA-2): rising ctDNA to tailor endocrine therapy switch in patients with ER+/HER2- metastatic breast cancer

2025-524213-84-00Patients with advanced or metastatic ER+ HER2- breast cancer

DrugsCamizestrant·Abemaciclib

Unicancer

Neoplasms

France

06/07/2026

Phase III

Macroleave: Impact of discontinuation of long-term macrolides in stable Non Cystic Fibrosis Bronchiectasis : a multicenter randomized controlled trial

2025-521493-33-00bronchiectasis unrelated to cystic fibrosis

DrugAzithromycin

Centre Hospitalier Intercommunal Creteil

Respiratory Tract Diseases

France

06/07/2026

Phase II

Immunogenicity and safety of two respiratory syncytial virus vaccine strategies in lung and allogeneic haematopoietic stem cell transplant recipients: A phase 2 trial RSVaxID

2025-524374-42-00allogeneic haematopoietic stem cell transplant recipient, l…

DrugVaxzevria

Hospices Civils De Lyon

Surgical Procedures, Operative

France

06/07/2026

Phase II

Shared decision-making in uncomplicated appendicitis: a pragmatic randomized trial comparing patient-driven choice (antibiotics only or appendectomy) with systematic appendectomy (FRENCH 47 — ALACARTE trial)

2025-520783-17-01Adult patients diagnosed with uncomplicated acute appendici…

Assistance Publique Hopitaux De Paris

Therapeutics

France

06/07/2026

Phase II

Feasibility of fluorescence imaging with bevacizumab-800CW during bronchoscopy in patients with a pulmonary lesion considered to be malignant - DFLECT I

2024-510793-24-00suspected malignant pulmonary disease (lung lesions and/or …

DrugBevacizumab

Universitair Medisch Centrum Groningen

Neoplasms

Netherlands

06/07/2026

Phase I

A study to investigate the repeat-dose pharmacokinetics of a combined oral contraceptive when given alone and in combination with ganfeborole in female participants of non-childbearing potential.

2026-525790-39-00Tuberculosis

Glaxosmithkline Research & Development Limited

Bacterial Infections and Mycoses

Spain

06/07/2026

Phase IV

Oral versus Intravenous Tranexamic Acid for Blood Loss Prevention in Off-Pump Coronary Artery Bypass Surgery: A Randomised Non-Inferiority Trial (TRANSCAB Study)

2026-526581-24-01Coronary artery disease requiring off-pump coronary artery …

DrugTranexamic Acid

Sante et Prevoyance

Cardiovascular Diseases

Belgium

06/07/2026

Phase III

A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype

2024-518016-39-00Respiratory tract diseases

Sanofi-Aventis Recherche & Developpement

Respiratory Tract Diseases

Denmark, Sweden, Poland, Estonia, Portugal, Latvia, Spain, Hungary, Germany, Finland, Italy, Belgium, France

06/07/2026

Phase III

2024-518213-25-00Respiratory tract diseases

Sanofi-Aventis Recherche & Developpement

Respiratory Tract Diseases

Germany, Romania, Greece, Norway, Netherlands, Poland, Lithuania, Czechia, Slovakia, Spain

06/07/2026

Phase I

A Phase 1 Study of TORL-1-23 in Advanced Cancer

2024-517189-40-00Advanced Cancer

Torl Biotherapeutics LLC

Neoplasms

Ireland

06/07/2026

Phase II

iSTOP-CP: intranasal Stem Cells to treat Perinatal brain injury to combat Cerebral Palsy

2025-521506-17-01Hypoxic-ischemic brain injury (HIBI) because of Perinatal A…

Universitair Medisch Centrum Utrecht

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Netherlands

06/07/2026

Phase IV

Efficacy, Safety, and Patient Satisfaction of Patient-Controlled Remimazolam Sedation in Outpatient Colonoscopy: A randomized controlled trial.

2026-525809-13-00The trial will study sedation related to colonoscopy, there…

Region Hovedstaden

Digestive System Diseases

Denmark

06/07/2026

Phase III

The RELEASE Trial: Reconsidering Long-Term Aspirin in the Elderly in Secondary Prevention of Cardiovascular Disease

2026-525442-30-00Ischemic heart disease/Chronic coronary syndrome (Myocardia…

Odense University Hospital

Cardiovascular Diseases

Denmark

06/07/2026

Phase IV

Optimising Arthritis Strategies in Elderly patients (≥70 years) with rheumatoid arthritis in sustained low disease activity (the OASE study): A Prospective Target Trial Emulation Study Evaluating Tapering of Disease-Modifying Anti-Rheumatic Drugs vs. Usual Care Based on Patient Preference

2026-525221-21-01Rheumatoid arthritis

DrugsCertolizumab Pegol·Sulfasalazine·Golimumab·Leflunomide

Aalborg University Hospital, Aalborg University Hospital

Musculoskeletal Diseases

Denmark

06/07/2026

Phase I/II

A Phase 1b-2, Open-Label, Dose-Escalation, Expansion and Optimization Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of LRK-4189 Alone and in Combination with mFOLFOX6 or FOLFIRI in Patients with Solid Tumors

2026-525629-20-00Solid tumors

Larkspur Biosciences Inc.

Neoplasms

France

03/07/2026

Phase I

Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants with End-Stage Kidney Disease on Hemodialysis

2026-525844-14-00End-Stage Kidney Disease (ESKD)

Regeneron Pharmaceuticals Inc.

Hemic and Lymphatic Diseases

Belgium

03/07/2026

Phase II

The Acute and Long-term Impact of Support in Psilocybin Therapy for Depression: The Psilocybin Setting Trial (PSISET)

2025-522961-31-01Depression

DrugPsilocybin

Kobenhavns Universitet, Koebenhavns Universitet

Mental Disorders

Denmark

03/07/2026

Phase II

Individualized Intrathecal Chemotherapy Based on Measurement of Brain Fluid Clearance in Pediatric Patients

2025-522453-20-00Acute lymphoblastic leukemia and lymphoma

DrugGadobutrol

Oslo University Hospital HF

Neoplasms

Norway

03/07/2026

Phase III

Dual-agent fluorescence-guided surgery for colorectal liver metastases

2025-524755-31-00Colorectal liver metastases

Leids Universitair Medisch Centrum (LUMC)

Digestive System Diseases

Netherlands

03/07/2026

Phase II

A Randomized, Delayed-Treatment Controlled, Phase 2 Pilot Study of Manualized MDMA-Assisted Therapy for Young Adults with Chronic Treatment-Resistant Major Depressive Disorder

2024-520319-42-01Major Depressive Disorder

DrugMidomafetamine HCl

Ostfold Hospital Trust

Psychological Phenomena

Norway

03/07/2026

Phase I

Calcium Electroporation for Urinary Bladder Tumors: A First-in-Human Feasibility, Safety, and Early Response Trial - The CALCIFER Trial

2026-526388-39-00Bladder cancer, Bladder tumors, Urothelial cancer, Urotheli…

Region Sjaelland

Female Urogenital Diseases and Pregnancy Complications

Denmark

03/07/2026

Phase II

A multicenter open-label phase II study of Cemiplimab plus chemotherapy, selected on the basis of baseline cytidine deaminase activity, in advanced squamous non-small cell lung cancer - CECYDE trial - GOIRC-04-2024

2024-517799-40-00Advanced squamous non-small cell lung cancer

DrugCemiplimab

G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica

Neoplasms

Italy

03/07/2026

Phase II

Interleukin-1 inhibition to improve the response of myeloproliferative neoplasms resistant to cytoreductive treatment

2025-523921-17-00myeloproliferative neoplasms

DrugAnakinra

Centre Hospitalier Regional Et Universitaire De Brest

Hemic and Lymphatic Diseases

France

02/07/2026

Phase II

18F-fluoro-ethyl-tyrosine (18FET) PET for difficult clinical situations in functional pituitary adenoma. A prospective, single arm, single center study. (FET-PIT)

2025-523829-17-00Patients (male or female) ≥18 years old with Suspected func…

Centre Hospitalier Universitaire De Lille

Diagnosis

France

02/07/2026

Phase I

Bioequivalence Study of Dapagliflozin 10 mg

2026-526840-10-00Not applicable (submitted trial is a BE study in healthy pa…

Vipharm S.A.

Cardiovascular Diseases

Czechia

02/07/2026

Phase II

IFCT-2501 IDEATION ctDNA-guIDEd consolidATION immunotherapy after chemoradiotherapy in patients with stage III non-small cell lung cancer

2025-522801-39-00Stage III Non Small Cell Lung Cancer

DrugDurvalumab

Intergroupe Francophone De Cancerologie Thoracique

Neoplasms

France

02/07/2026

Phase I

Network pharmacology-based personalized drug repurposing in thyroid carcinoma: a pilot feasibility trial

2023-507214-28-00Advanced thyroid cancer

Stichting Radboud University Medical Center

Neoplasms

Netherlands

02/07/2026

Phase III

AugmENtation witH cAnnabidiol iN first episode psyChosis: a doublE blind randomised controlled trial (STEP-ENHANCE Trial)

2025-521929-32-01First Episode Psychosis (FEP)

DrugCannabidiol

University Of Oxford

Mental Disorders

Netherlands, Greece, Germany, Italy, Austria, Spain

01/07/2026

Phase I/II

A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE849 in Patients with DLL3 Expressing Tumors Including Small Cell Lung Cancer

2025-523438-24-00DLL3 Expressing Tumors Including Small Cell Lung Cancer

DrugDurvalumab

Ideaya Biosciences Inc.

Neoplasms

France, Spain

01/07/2026

Phase III

"A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma after 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide"

2025-523815-12-00Relapsed or Refractory Multiple Myeloma

Janssen Cilag International

Neoplasms

Poland, Spain, Czechia, France, Italy, Germany, Greece

01/07/2026

Phase II

High-dose Insulin Euglycemic Therapy in Non-Toxic Acute Cardiogenic Shock.

2025-523858-13-01Non-toxic acute cardiogenic shock

DrugHumalog

Oslo Universitetssykehus HF

Cardiovascular Diseases

Norway

01/07/2026

Phase I

A phase 1b trial to study the safety and effect of ZP9830 in patients with plaque psoriasis

2026-525220-15-00Plaque Psoriasis

Zealand Pharma A/S

Skin and Connective Tissue Diseases

Netherlands

01/07/2026

Phase I

An open label, balanced, randomized, single dose, two-treatment, two period, two-sequence, crossover, bioequivalence study comparing Fexofenadine HCl and Pseudoephedrine HCl Extended Release Tablet 180 mg/240 mg, Manufactured by: Sun Pharmaceutical Industries Limited, India with Allegra-D® 24 HR (Fexofenadine HCl and Pseudoephedrine HCl Extended Release Tablets 180 mg + 240 mg) tablets, Distributed by: Chattem Inc., a Sanofi Company Chattanooga, TN 37409-0219, USA, in healthy, adult, human participants under fed conditions.

2026-525421-20-00Seasonal allergic rhinitis

Sun Pharmaceutical Industries Limited

Immune System Diseases

Romania

01/07/2026

Phase I

An open label, balanced, randomized, single dose, two-treatment, four period, two-sequence, crossover, fully replicate, bioequivalence study comparing Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended Release Tablet USP 180 mg/240 mg, Manufactured by: Sun Pharmaceutical Industries Limited, India with Allegra-D® 24 HR (Fexofenadine HCl and Pseudoephedrine HCl Extended Release Tablets 180 mg + 240 mg) tablets, Distributed by: Chattem Inc., a Sanofi Company Chattanooga, TN 37409-0219, USA, in healthy, adult, human participants under fasting conditions.

2026-525420-22-00Seasonal allergic rhinitis

Sun Pharmaceutical Industries Limited

Immune System Diseases

Romania

01/07/2026

Phase I/II

The headache- and migraine-inducing effects of apremilast in women with migraine without aura

2026-525987-16-00Migraine without aura

DrugApremilast

Syddansk Universitet (University of Southern Denmark)

Nervous System Diseases

Denmark

01/07/2026

Phase II

A Phase II, Randomized, Double-blind, 3-Period Cross-over, Dose‑ranging Study to Assess the Efficacy and Safety of Glycopyrronium (GP) versus Placebo in Participants of 4 to Less than 12 Years of Age with Asthma Receiving Background Budesonide and Formoterol Fumarate (BFF) (FAROS)

2025-524914-26-00Asthma

AstraZeneca AB

Respiratory Tract Diseases

Czechia, Poland, Hungary

01/07/2026

Phase I

A Study to Evaluate Targeted Therapies for Patients with Rheumatoid Arthritis

2025-523127-21-00Rheumatoid Arthritis

AbbVie Deutschland GmbH & Co. KG

Immune System Diseases

Belgium, Netherlands, Spain, Germany, Italy

01/07/2026

Phase I

A study in healthy men to find out how blocking certain transport proteins affects the amount of BI 3000202 in the blood

2026-525549-60-00Healthy

Boehringer Ingelheim International GmbH

Not possible to specify

Germany

01/07/2026

Phase III

A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment After 2L PlatinumBased Doublet Chemotherapy in Participants With Recurrent Platinum-Sensitive Ovarian Cancer (PSOC)

2025-522167-15-00Ovarian Cancer Platinum-Sensitive Ovarian Cancer (PSOC)

DrugBevacizumab

Genmab A/S

Neoplasms

Finland, Belgium, Hungary, France, Denmark, Austria, Germany, Italy, Spain, Czechia, Norway, Poland

01/07/2026

Phase I

C6501003 - A Phase 1, Open-Label, Randomized, Single Dose, Parallel Group Study to Assess Relative Bioavailability of PF-08653945 When Administered Across Different Injection Sites in Adults With Overweight or Obesity

2026-526334-67-00chronic weight management and other weight-related co-morbi…

Pfizer Inc.

Nutritional and Metabolic Diseases

Belgium

01/07/2026

Phase I

A study in healthy men to test how BI 1815368 is processed in the body

2025-523949-10-00Healthy volunteers trial

Boehringer Ingelheim International GmbH

Not possible to specify

Netherlands

30/06/2026

Phase IV

Progesterone Luteal Support in Unexplained Infertility Management (PLUIM study)

2026-525747-33-00unexplained subfertillity, infertillity

DrugProgesterone

Universitair Medisch Centrum Utrecht

Female Urogenital Diseases and Pregnancy Complications

Netherlands

30/06/2026

Phase I

Evaluation of bioequivalence of two products containing estradiol: Estradiol/INTERMED gel 0.1% w/w (Test) vs. ESTREVA 0.1% gel (Comparator). An open, randomized, single-dose, four-period, full-replicative trial in healthy postmenopausal women

2025-524775-23-00No therapeutic indication in the current trial with healthy…

CCDRD Cooperative Clinical Drug Research and Development AG, Ioulia And Irene Tseti Pharmaceutical Laboratories S.A.

Physiological processes

Bulgaria

30/06/2026

Phase I/II

A Phase 1/2 Study of Inhaled KB707 in Patients with Advanced Solid Tumor Malignancies Affecting the Lungs

2025-522723-98-00solid tumor

Krystal Biotech Inc.

Neoplasms

France, Spain

30/06/2026

Phase III

Phase III, Open-label Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, Efficacy, and Immunogenicity of Benralizumab in Children with Eosinophilic Disease (CLIPS)

2023-508533-14-00Eosinophilic Disease

DrugBenralizumab

AstraZeneca AB

Immune System Diseases

Poland, Netherlands, France

30/06/2026

Phase II

A phase IIa, single-arm, single-center, open label, proof-of-concept trial evaluating increased frequency dosing of VCN-01 (zabilugene almadenorepvec) in combination with nab-Paclitaxel/Gemcitabine (GnP) in Patients with Newly-Diagnosed Metastatic Pancreatic Cancer (VIRAGE2)

2026-525566-21-00metastatic pancreatic adecarcinoma

Theriva Biologics S.L.

Neoplasms

Spain

30/06/2026

Phase III

A Phase 3 Multicenter Double-blind Randomized Study of Taletrectinib Versus Placebo in Patients With ROS1-Fusion Positive Stage IB-IIIA Non-Small Cell Lung Cancer Who Have Undergone Complete Tumor Resection

2025-521971-29-00Non Small Cell Lung Cancer (NSCLC)

DrugTaletrectinib

Nuvation Bio Inc.

Respiratory Tract Diseases

Spain, Belgium, France, Italy, Germany

30/06/2026

Phase III

A Long-term Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

2025-521769-29-00Pulmonary Hypertension Associated with Interstitial Lung Di…

DrugTreprostinil Palmitil

Insmed Inc.

Respiratory Tract Diseases

Greece, France, Italy, Belgium, Denmark, Germany, Poland, Czechia, Portugal, Austria, Spain, Romania

30/06/2026

Phase I/II

Phase 1-2, Open-Label, Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION337 in Patients with Dravet Syndrome

2025-523835-20-00Dravet Syndrome

Ionis Pharmaceuticals Inc.

Nervous System Diseases

Spain, France, Belgium, Portugal, Germany

30/06/2026

Phase I

A double-blind, prospective, randomised, placebo-controlled, single-centre, proof-of-principle trial in healthy volunteers to investigate safety, local tolerability, pharmacokinetics, and pharmacodynamics of Asacaine after topical administration on skin exposed to ultraviolet B radiation

2026-526022-41-00Topical pain

Auxesis Pharma Holding AB (publ)

Skin and Connective Tissue Diseases

Sweden

30/06/2026

Phase III

Efficacy and safety of Dalbavancin in the treatment of infective Endocarditis caused by gram-positive cocci

2026-526149-91-00Infectious endocarditis caused by Gram-positive cocci (stap…

DrugsAmpicillin·Cefaclor·Cefotaxime·Dalbavancin

Friedrich-Schiller-Universitaet Jena

Cardiovascular Diseases

Germany

30/06/2026

Phase III

A Phase 2/3 Study to Characterize and Evaluate the Efficacy, Safety, and Tolerability of hu14.18K322A Treatment Given in Combination with Chemotherapy in Participants with High-Risk Neuroblastoma

2025-524397-42-00Participants with relapsed HRNB and participants with HRNB…

DrugsTemozolomide·Irinotecan

Renaissance Pharma Limited

Nervous System Diseases

France, Spain, Denmark, Ireland, Germany

30/06/2026

Phase I

A study to compare how the body absorbs 4 different forms of norucholic acid medicine (tablets, granules, and capsules) when taken with or without food in healthy adults

2025-523778-17-00Not applicable, healthy volunteers

Dr. Falk Pharma GmbH

Not possible to specify

Germany

30/06/2026

Phase I

A Phase 1 Randomized, Double-Blind, placebo-controlled, clinical study to evaluate safety and Pharmacokinetics, of Single Ascending Doses and Multiple Ascending Doses of AIK3a305 in Healthy Volunteers

2026-525830-49-00Treatment of several inflammatory diseases, including infla…

Allinky Biopharma S.L.

Not possible to specify

Spain

29/06/2026

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants with Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care

2025-524855-30-00Cutaneous Manifestations of Lupus Erythematosus With or Wit…

Merck Healthcare KGaA

Skin and Connective Tissue Diseases

Germany, Romania, France, Bulgaria, Belgium, Spain, Poland, Greece, Italy, Czechia

29/06/2026

Phase III

2025-523871-44-00Cutaneous Manifestations of Lupus Erythematosus With or Wit…

Merck Healthcare KGaA

Immune System Diseases

Spain, Belgium, France, Germany, Slovakia, Romania, Bulgaria, Italy, Poland, Greece

29/06/2026

Phase III

AndroMETa-CRC-560: An Open-Label, Randomized, Controlled, Global Phase 3 Study Comparing Telisotuzumab Adizutecan (ABBV-400) plus Bevacizumab to LONSURF (Trifluridine and Tipiracil) plus Bevacizumab in Subjects with Refractory Metastatic Colorectal Cancer

2025-521712-19-00Colorectal Cancer

AbbVie Deutschland GmbH & Co. KG

Neoplasms

Greece, Portugal, Germany, Belgium, Spain

29/06/2026

Phase III

Methoxyflurane versus Standard Care for Non-Traumatic Pain in the Emergency Department (PAIN-THROX) : A Multicenter, Randomized, Controlled, Superiority Trial

2025-525001-21-00Non-traumatic pain

DrugMethoxyflurane

Centre Hospitalier Regional Universitaire De Tours

Not possible to specify

France

29/06/2026

Phase II

C6461014 - A Phase 2 Interventional Study of PF-08634404 in Combination with Chemotherapy in Participants with Previously Untreated Transformed Small Cell Lung Cancer

2025-524686-24-00Small Cell Lung Cancer

DrugsPF-08634404·Etoposide·Carboplatin

Pfizer Inc.

Neoplasms

France, Italy, Spain

29/06/2026

Phase II

Randomised open-label pilot Study on Thiamine supplementation to REduce braiN injury associated with chronic Alcohol use in outpatients with alcohol use disorder : STRENA

2025-524148-36-00Alcoholism

Institut National De La Sante Et De La Recherche Medicale

Mental Disorders

France

29/06/2026

Phase IV

ObStructive Sleep Apnoea ManageMent in Older AdUlts with Overweight or ObEsity: A Randomized ClinicaL Trial (SAMUEL study)

2026-525500-10-00Obstructive sleep apnea syndrome, Obesity

DrugTirzepatide

Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre

Nutritional and Metabolic Diseases

Spain

29/06/2026

Phase II

A Master Protocol of a Phase II, Open-label, Multicenter, Global Platform Study to Evaluate the Safety and Efficacy of Immunotherapy With or Without Other Anticancer Drugs in Participants with Unresectable Stage III Non-small Cell Lung Cancer Planning to Undergo Concurrent Chemoradiotherapy (AQUARIUS)

2025-523599-21-00Non-small Cell Lung Cancer

DrugsMycophenolate Mofetil·Infliximab·Rilvegostomig·Pemetrexed

AstraZeneca AB

Neoplasms

Spain, Germany

29/06/2026

Phase I/II

PET imaging For eaRly predictiOn of respoNse to neoadjuvanT tReatment in lUNg caNcER

2025-524791-30-00Non small cell lung cancer

Radboud universitair medisch centrum Stichting

Respiratory Tract Diseases

Netherlands, Germany

29/06/2026

Phase I/II

A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) inhibitors in Combination with Ivonescimab with or without Other Anti-Cancer Agents in Patients with Solid Tumors

2025-524623-50-00Solid Tumors

DrugsElironrasib·RMC-9805·Erbitux·Ivonescimab

Revolution Medicines Inc.

Neoplasms

France, Poland, Ireland, Spain, Greece, Germany, Italy, Sweden, Belgium

29/06/2026

Phase III

CLARITHROMYCIN TO PREVENT SECONDARY INFECTIONS IN PATIENTS WITH SEPSIS FOLLOWING LOWER RESPIRATORY TRACT INFECTIONS: THE CLASSIFY TRIAL

2025-525058-20-00Community- acquired pneumonia related sepsis with evidence …

Elliniko Institouto Meletis Tis Sipsis

Respiratory Tract Diseases

Greece

29/06/2026

Phase I

LAFOV-Lung PET

2026-525834-45-00Investigation in healthy volunteers

Medical University Of Vienna

Diagnosis

Austria

29/06/2026

Phase I

First study evaluating the safety and dosage of YG-01 in patients with a malignant brain tumor

2025-524299-44-00Glioblastoma

Ygion Biomedical GmbH

Neoplasms

Austria

29/06/2026

Phase III

A Randomized Phase III Study to Investigate the Efficacy and Safety of Alpha1H as a Neoadjuvant Therapy in Participants with Low- to Intermediate-Risk/Low-Grade Papillary Non-Muscle Invasive Bladder Cancer

2026-525531-16-00Non-Muscle Invasive Papillary Bladder Cancer

Hamlet BioPharma AB

Male Urogenital Diseases

Czechia

29/06/2026

Phase IV

Unprescribing the Pill to Reassess Symptom and Cognitive Recovery in Depression (UNPRESCRIB-D)

2026-526314-90-00Major Depressive Disorder

DrugsSertraline·Duloxetine

Region Hovedstaden

Mental Disorders

Denmark

29/06/2026

Phase III

Self-Assessment Method for Statin side-effects Or Nocebo 2

2025-524955-30-01Cardiovascular diseases

DrugRosuvastatin

Copenhagen University Hospital, Region Hovedstaden

Musculoskeletal Diseases

Denmark

28/06/2026

Phase III

A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)

2025-525009-18-00Pancreatic Ductal Adenocarcinoma

Incyte Corp.

Neoplasms

Poland, Italy, Netherlands, Sweden, Denmark, Finland, Spain, France, Germany, Belgium, Norway, Austria

26/06/2026

Phase I

A Phase 1 Study of BMS-986460 in Metastatic Castration-resistant Prostate Cancer

2024-513987-24-00Metastatic Castration-resistant Prostate Cancer

Bristol-Myers Squibb Services Unlimited Company

Neoplasms

France

26/06/2026

Phase IV

Randomized Evaluation of fleCAinide safety vs. STandard of care in patients with coronary artery disease and Atrial Fibrillation (ReCAST AF).

2025-525121-13-00Coronary artery disease, Atrial fibrillation

UZ Leuven

Cardiovascular Diseases

Belgium

26/06/2026

Phase IV

Prospective, multicenter, randomized study on combined LT4 + LT3 therapy versus LT4 in the control of TSH in patients with advanced thyroid cancer treated with tyrosine kinase inhibitors.

2026-526113-28-00Advanced thyroid carcinoma. Post-thyroidectomy hypothyroidi…

Ceinge Biotecnologie Avanzate Franco Salvatore S.c.a.r.l.

Hormonal diseases

Italy

26/06/2026

Phase I

Three-part PK and PD study of AXN-027

2025-524019-35-00Chronic pain, refractory epilepsy, and other neurological d…

Axonis Therapeutics Inc.

Nervous System Diseases

Netherlands

26/06/2026

Phase IV

Short and long-term Hemodynamic and Physiological Effects of Mavacamten in Obstructive Hypertrophic Cardiomyopathy

2025-524722-17-00Obstructive Hypertrophic Cardiomyopathy

Region Skane

Cardiovascular Diseases

Sweden

26/06/2026

Phase II

“In vivo” biological standardization of the allergenic extracts Dermatophagoides pteronyssinus (DPT) and Dermatophagoides farinae (DF) in patients sensitized to them.

2026-525628-13-00IgE-mediated respiratory allergic disease due to the allerg…

Probelte Pharma S.L.

Disorders of Environmental Origin

Spain

26/06/2026

Phase III

A 2-Part, Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study to Assess Efficacy and Safety of REGN7508, a Monoclonal Antibody Against Factor XI, for the Treatment and Secondary Prevention of Venous Thromboembolism in Participants with Solid and Hematologic Cancers (ROXI-CAT-II)

2024-519299-16-00Cancer Associated Thrombosis

Regeneron Pharmaceuticals Inc.

Cardiovascular Diseases

Bulgaria, Romania

26/06/2026

Phase I

Skin irritation and sensitization trial

2026-525269-34-00The intended indication is for the treatment of major depre…

CCDRD Cooperative Clinical Drug Research and Development AG, Corium Innovations Inc.

Mental Disorders

Bulgaria

26/06/2026

Phase III

Colchicine after Electrocardioversion for Atrial Fibrillation - The COLECTRO-AF Trial

2024-516033-12-00Atrial Fibrillation

Universitaetsspital Basel

Cardiovascular Diseases

Germany

26/06/2026

Phase IV

Phase IV study evaluating the efficacy and safety of the venetoclax + rituximab (VR) regimen in patients with relapsed chronic lymphocytic leukemia in Polish clinical practice

2025-524795-35-00Adult with chronic lymphocytic leukemia/small lymphocytic l…

DrugsVenetoclax·Rituximab

Uniwersytet Medyczny W Lublinie

Hemic and Lymphatic Diseases

Poland

26/06/2026

Phase III

Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe year AfTer lIver transplantatiON (ALTERNATION) – a randomized, prospective, multicenter, open-label, controlled phase III trial

2025-524312-11-00Patients after the first year following liver transplantati…

Medizinische Hochschule Hannover

Therapeutics

Germany

26/06/2026

Phase IV

A multicentre, adaptive, randomised, multidomain, platform trial for dose optimization in the treatment of adult patients with haematological diseases (BLOOD-dose): core protocol

2026-525658-13-00Haematological diseases; any disorder that primarily affect…

DrugsLinvoseltamab·Talquetamab·Elranatamab·Teclistamab

Region Hovedstaden

Hemic and Lymphatic Diseases

Denmark

25/06/2026

Phase III

Evaluating the effect of inhaled levodopa (Inbrija®) for early morning off in Parkinson’s disease

2026-526465-18-00parkinson's disease

DrugLevodopa

Region Hovedstaden

Nervous System Diseases

Denmark

25/06/2026

Phase I

A Phase 1 Study of LBL-051 in Patients with Refractory Autoimmune Disease

2026-525621-20-00B-cell–mediated autoimmune diseases

Oblenio Bio Inc.

Immune system processes

Germany, Romania, Poland

25/06/2026

Phase I

Phase 1 Single Dose Study of JADE201 in Participants with Rheumatoid Arthritis

2025-524746-96-00Rheumatoid Arthritis

Jade Biosciences Inc.

Immune System Diseases

Romania, Bulgaria, Germany

25/06/2026

Phase II

An open-label multiple dose safety, tolerability and exploratory efficacy clinical trial of PST-611 in patients with geographic atrophy secondary to age-related macular degeneration

2025-525008-12-00Geographic atrophy secondary to age-related macular degener…

PulseSight Therapeutics

Eye Diseases

France

25/06/2026

Phase IV

ECETEP : Pilot study evaluating PSMA positron emission tomography for monitoring clinically significant prostate cancer after focal HIFU treatment

2026-525181-22-00prostate cancer

DrugPiflufolastat

Centre Hospitalier Universitaire De Toulouse

Diagnosis

France

25/06/2026

Phase III

A PHASE III, OPEN-LABEL, SINGLE-ARM, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND USE OF AN ON-BODY DELIVERY SYSTEM FOR THE SUBCUTANEOUS HOME ADMINISTRATION OF OCRELIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS

2025-523726-40-00Multiple Sclerosis

F. Hoffmann-La Roche AG

Immune System Diseases

Spain, France, Poland, Italy

24/06/2026

Phase IV

Morphine for resting breathlessness in severe illness and palliative care (MORE-B): a randomized clinical trial

2026-525838-32-00Serious, chronic, life-limiting disease

Region Skane

Respiratory Tract Diseases

Sweden

24/06/2026

Phase III

Women victims of violences : PTSD treatment by traumatic memory reactivation under the influence of propranolol (VIOFEM)

2025-523107-30-01Post-traumatic stress disorder (PTSD)

DrugPropranolol

Centre Hospitalier Universitaire De Toulouse

Mental Disorders

France

24/06/2026

Phase I

A single and multiple dose trial assessing safety, tolerability, pharmacokinetics and pharmacodynamics of ZP6590

2026-525978-19-00Weight management

Zealand Pharma A/S

Nutritional and Metabolic Diseases

Germany

24/06/2026

Phase I

Systemic Bioavailability and Bioequivalence of Topical Diclofenac Fysioline 23.2 mg/g gel compared with Diclofenac Diethylamine - Voltaren Forte 2.32% gel

2026-526434-21-00Bioequivalence, musculoskeletal pain pain

Fysioline Oy

Anesthesia and Analgesia

Finland

24/06/2026

Phase I

THERIPEX - A phase I/II open label non-randomized study, monocentric, single-arm, evaluating Safety and Efficacy of induced T-CD4 Treg by LV vector transduction expressing the FoxP3 cDNA in patients with IPEX syndrom

2025-523305-15-00Patients affected by IPEX syndrome, proven by molecular di…

Assistance Publique Hopitaux De Paris

Immune System Diseases

France

24/06/2026

Phase III

ALBUMINUS: Dose reduction of human albumin during large-volume paracentesis in patients with cirrhosis

2026-526167-38-00liver cirrhosis

Amsterdam UMC Stichting

Digestive System Diseases

Netherlands

23/06/2026

Phase IV

The impact of ovarian stimulation with hMG on embryo quality in advanced age women. A randomized controlled trial

2025-524761-25-00infertility

DrugsFollitropin delta·Progesterone

Santiago Dexeus Font Fundacio Privada

Female Urogenital Diseases and Pregnancy Complications

Spain

23/06/2026

Phase II

A Randomized, Double-blinded, Placebo-controlled, Parallel Group, Phase 2a Study to Assess the Activity, Safety, and Tolerability of SAR445399 in Adult Participants with Non-Cystic Fibrosis Bronchiectasis (NCFB).

2025-523403-29-00Non-cystic fibrosis bronchiectasis

Sanofi-Aventis Recherche & Developpement

Respiratory Tract Diseases

Poland, Spain, France, Netherlands, Germany

23/06/2026

Phase III

Multicenter Interventional Study Somatrogon Impact on Outcomes in Naive Small for Gestational Age or Idiopathic Short Stature paediatric patients compared with daily growth hormone

2025-523832-38-00Small for gestational age (SGA) and idiopathic short statur…

DrugsSomatrogon·Somatropin

Schneider Children's Medical Center Of Israel

Musculoskeletal Diseases

Greece, Poland, France, Czechia

23/06/2026

Phase IV

USEFULNESS OF HIGH-FLOW OXYGEN THERAPY TO IMPROVE THE SAFETY OF PATIENTS AT HIGH RISK OF HYPOXEMIA UNDERGOING DIGESTIVE ENDOSCOPY UNDER DEEP SEDATION: A RANDOMIZED MULTICENTER COMPARATIVE STUDY. THE ENDOALF-TRIAL.

2026-525766-21-01Hypoxemic episodes in patients undergoing gastroscopy, colo…

Hospital Universitario Rio Hortega

Respiratory Tract Diseases

Spain

23/06/2026

Phase III

ECSIP : Early Corticosteroids in Severe Influenza Pneumonia, a phase III randomized controlled trial

2025-524976-40-00patients with influenza-induced acute hypoxemic respiratory…

DrugDexamethasone

Centre Hospital Region Metz Thionville

Respiratory Tract Diseases

France

23/06/2026

Phase II

An Open-Label Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents with Relapsing-Remitting Multiple Sclerosis

2025-524164-37-00Relapsing-Remitting Multiple Sclerosis (RRMS)

DrugOcrelizumab

F. Hoffmann-La Roche AG

Nervous System Diseases

Poland, Germany, France

23/06/2026

Phase II

A Phase IIb, Non-Profit, Open-label Trial for the Intrathecal Administration of AAV9/AP4M1 for Hereditary Spastic Paraplegia Type 50 (SPG50).

2025-524481-15-00Heriditary spastic paraplegia (SPG50)

Rigshospitalet, Elpida Therapeutics SPC

Nervous System Diseases

Denmark

23/06/2026

Phase IV

Treatment strategies for juvenile idiopathic arthritis patients with sustained inactive disease: A phase 4, multicentre, randomised trial comparing maintenance versus tapered TNF alpha inhibitor monotherapy - the Treat-JIA trial

2026-525611-13-00Juvenil Idiopatic Arthritis

DrugsGolimumab·Etanercept·Adalimumab

Oslo Universitetssykehus HF

Musculoskeletal Diseases

Norway

23/06/2026

Phase III

SERENDIPITY: phase III multicentric randomized study assessing the reduction of chronic prostate inflammation with Permixon®

2025-525123-27-00Benign prostatic hypertrophy

Azienda Ospedaliero Universitaria Careggi, University Of Florence

Male Urogenital Diseases

Italy

23/06/2026

Phase III

A Prospective, Randomized, Controlled, Multinational, Phase 2/3, Open-Label Trial to Evaluate the Efficacy and Safety of SIL204-SL Administered as an Integrated Therapeutic Regimen in Combination with Chemotherapy vs. Chemotherapy Treatment Alone in Participants with Locally Advanced Pancreatic Cancer

2025-525157-39-00Non-Resectable Locally Advanced Pancreatic Cancer (LAPC)

Silexion Therapeutics Ltd.

Neoplasms

Germany

23/06/2026

Phase II

Efficacy of asciminib in chronic phase CML patients with T315l mutations

2025-523491-23-00Chronic Myeloid Leukemia

DrugAsciminib

Friedrich-Schiller-Universitaet Jena

Neoplasms

Germany

23/06/2026

Phase III

A Phase 3 Extension Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema

2025-521353-16-00Hereditary Angioedema

DrugDopamine

Adarx Pharmaceuticals Inc.

Immune System Diseases

Poland, Italy, Hungary, France, Austria, Czechia, Belgium, Spain, Bulgaria, Germany, Croatia

22/06/2026

Phase I/II

Exploratory study of the performance of dynamic PET-CT acquisition to predict 6-month morphological response in patients with hepatocellular carcinoma treated with selective internal radiotherapy

2026-526324-48-00HCC – Hepatocellular Carcinoma

Centr Georges Francois Leclerc

Neoplasms

France

22/06/2026

Phase III

A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Non-Active Secondary Progressive Multiple Sclerosis

2025-524322-18-00Non-active Secondary Progressive Multiple Sclerosis (SPMS)

DrugOrelabrutinib

Zenas Biopharma (USA) LLC

Nervous System Diseases

Germany, Bulgaria, Netherlands, Sweden, Portugal, Croatia, Italy, Austria, Spain, Poland, France, Denmark, Hungary, Romania, Estonia, Slovakia, Belgium, Czechia, Norway, Lithuania, Greece, Slovenia

22/06/2026

Phase II

An Open-label, Single-Arm, Phase 2 Study to Evaluate Enfortumab Vedotin plus Pembrolizumab for Bladder Preservation in Participants with Muscle-invasive Bladder Cancer (EV-209).

2025-524488-18-00Muscle-invasive Bladder Cancer

Astellas Pharma Global Development Inc.

Neoplasms

Germany, France, Poland, Italy, Spain

22/06/2026

Phase II

A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-8690 in Adult Participants with Moderately to Severely Active Ulcerative Colitis

2025-523479-49-00Colitis ulcerative

Merck Sharp & Dohme LLC

Digestive System Diseases

Italy, Greece, Netherlands, Poland, Germany, France

22/06/2026

Phase II

Open-Label Extension Study to Provide Continued Access to Avutometinib Alone or in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

2025-524713-88-00Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

Verastem Inc.

Neoplasms

France

22/06/2026

Phase I/II

A Randomized, Double-Blind, Placebo-Controlled, Phase 1 / 2 Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Single Ascending Doses of TRCN-1023 Administered by Intrathecal Injections to Adult People Living with Amyotrophic Lateral Sclerosis

2025-523111-11-00Amyotrophic lateral sclerosis

Trace Neuroscience Inc.

Musculoskeletal Diseases

Germany, Netherlands

22/06/2026

Phase IV

Sample Collection Study to Monitor the Risk of Malignancy Due to Insertional Oncogenesis in Early Onset Patients with Metachromatic Leukodystrophy Treated with OTL-200 in the Clinical Development Program

2025-522275-28-00Metachromatic leukodystrophy

Orchard Therapeutics (Europe) Limited

Musculoskeletal Diseases

Netherlands, Germany, Italy, Sweden, France

22/06/2026

Phase I

Safety and Tolerability of REGN17235 in Adult Participants with Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome with SF3B1 Mutation

2026-525464-18-00Clonal Cytopenia of Undetermined Significance with SF3B1 mu…

Regeneron Pharmaceuticals Inc.

Neoplasms

Belgium

22/06/2026

Phase II

Psilocybin-Assisted Psychotherapy for Posttraumatic Stress Disorder in Military Veterans: A Pilot Feasibility Study

2025-521488-11-00Posttraumatic stress disorder

DrugPsilocybin

ARQ National Psychotrauma Centrum

Mental Disorders

Netherlands

22/06/2026

Phase II

Supplementary Oxygen Therapy after Limb Debridement and Reconstruction Surgery in Infected Extremity Fractures (SOLDIER): a pilot, non-blinded, randomized controlled trial

2026-525871-24-00Fracture-Related Infection

Amsterdam UMC Stichting

Bacterial Infections and Mycoses

Netherlands

22/06/2026

Phase II

A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 for the Treatment of Narcolepsy with Cataplexy (Narcolepsy Type 1)

2025-522587-33-00Narcolepsy with Cataplexy (NT1)

Takeda Development Center Americas Inc.

Nervous System Diseases

Spain, Italy, France

22/06/2026

Phase II

Pain Relief at Screening for Retinopathy of Prematurity - The PROPER study

2023-507975-23-01Retinopathy of prematurity

DrugDexmedetomidine

St. Olavs Hospital HF

Eye Diseases

Norway

22/06/2026

Phase III

Effects of bempedoic acid/ezetimibe/high-intensity statin on plaque regression and stabilisation of coronary atherosclerosis among patients without cardiovascular events

2025-524625-41-00Coronary atherosclerosis

Daiichi Sankyo Europe GmbH

Cardiovascular Diseases

Italy, Spain, Germany

22/06/2026

Phase II

A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of AGA2115 in Adults with Type I, III, or IV Osteogenesis Imperfecta (OI)

2025-522951-24-00Osteogenesis Imperfecta

DrugAGA2115

Angitia Inc. Ltd.

Musculoskeletal Diseases

Netherlands, France, Denmark

22/06/2026

Phase I

Pharmacokinetics, safety, and immunogenicity comparison of Bmab1700 and Opdivo® as adjuvant monotherapy in patients with melanoma

2025-525158-20-00Stage IIB/C, Stage III, or Stage IV Melanoma

Biocon Biologics UK PLC

Neoplasms

Spain, Romania

22/06/2026

Phase II

A Phase 2, Randomized, Double-blind, Placebo-controlled Crossover Study Evaluating the Efficacy and Safety of LTG-321 in Patients with Osteoarthritis of the Knee

2026-525966-22-00Osteoarthritis of the knee

Latigo Biotherapeutics Inc.

Musculoskeletal Diseases

Denmark

22/06/2026

Phase III

A Phase 3, Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of BMS-986353, CD19-targeted NEX-T CAR T Cells, Versus Standard of Care in Participants with Active Systemic Sclerosis (Breakfree-SSc)

2025-524337-11-00Systemic Sclerosis

DrugsNintedanib·Tocilizumab·Fludarabine·Rituximab

Celgene Corp.

Immune System Diseases

Spain, Germany, France, Italy, Belgium

19/06/2026

Phase I

A Phase 1 first-in-human study to evaluate SAR448272 in adult participants

2026-526014-87-00healthy volunteers, immunological diseases

Sanofi-Aventis Recherche & Developpement

Immune System Diseases

Germany, Czechia, France, Spain, Italy

19/06/2026

Phase IV

Insulin resistance in type 2 diabetes: evaluating the pathogenic mechanisms of insulin resistance in the myocardium and the effects of the treatments with GLP-1RA and SGLT2i

2025-523374-17-03Type 2 diabetes

DrugsDapagliflozin·Semaglutide

Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca

Nutritional and Metabolic Diseases

Spain

19/06/2026

Phase II

Epcoritamab in Relapsed/Refractory Marginalzone Lymphoma - A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY (EPOS-1)

2025-524879-23-00Marginal Zone Lymphoma

Universitaetsklinikum Ulm AöR

Hemic and Lymphatic Diseases

Germany

19/06/2026

Phase IV

Tacrolimus as prophylaxis of post-ERCP pancreatitis: a DPSG (Dutch Pancreatitis Study Group) multicenter, double-blind, randomized, placebo-controlled study.

2025-522900-26-00Post-ERCP Pancreatitis

Amsterdam UMC Stichting

Digestive System Diseases

Netherlands

19/06/2026

Phase I

A study to see how safe a new medicine (NNC6022-0004) is in healthy people and people living with obesity

2026-525179-26-00Cardiometabolic

Novo Nordisk A/S

Not possible to specify

Netherlands

19/06/2026

Phase I/II

Long-term Follow-up (LTFU) Study of Participants in any iECURE Protocol Using an Investigational Product

2024-514190-21-00Ornithine Transcarbamylase Deficiency (OTC)

Iecure Inc.

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Spain, France, Slovenia

18/06/2026

Phase I

A first study in healthy volunteers to examine the safety and tolerability of convalescent plasma given through the nose, as well as the duration of its presence in the nose

2025-525085-29-00Healthy volunteers

Rode Kruis-Vlaanderen

Respiratory Tract Diseases

Belgium

18/06/2026

Phase I

A Study to Learn How Different Amounts of the Study Intervention Called PF-07832837 are Tolerated and Act in the Body in Healthy Adults and Patients

2025-524150-34-00Atopic Dermatitis

Pfizer Inc.

Skin and Connective Tissue Diseases

Poland

18/06/2026

Phase I

A study to check whether adding RUTI® to standard BCG treatment for high-risk early-stage bladder cancer is safe and how it changes the body’s defenses, with participants randomly receiving RUTI® or a look-alike treatment.

2026-525897-20-00High-risk non-muscle invasive bladder cancer (NMIBC)

Laboratorio Reig Jofre S.A.

Male Urogenital Diseases

Spain

18/06/2026

Phase III

Paclitaxel plus ramucirumab and tislelizumab as switch maintenance versus continuation of chemotherapy and tislelizumab in patients with advanced HER2-negative and PD-L1 positive gastroesophageal adenocarcinoma: the ARMANI-2/ENGIC08 trial by GONO

2025-524048-36-00Advanced HER2-negative and PD-L1 positive gastroesophageal …

DrugsCalcium folinate·Ramucirumab·Fluorouracil·Tislelizumab

Fondazione GONO G.I.

Neoplasms

Spain, Germany, Italy

18/06/2026

Phase II

A randomized, double-blind, placebo-controlled, 104-week proof-of-concept study to evaluate the efficacy of intravenous prasinezumab in participants with Parkinson's disease carrying a severe mutation in the GBA gene (prevent cognitive decline in GBA-associated PD)

2024-513496-40-00PARKINSON’S DISEASE

DrugPrasinezumab

Universitaetsklinikum Tuebingen AöR

Nervous System Diseases

Spain, Germany, Italy, Sweden, France, Luxembourg

18/06/2026

Phase III

A multicentre, randomized, double-blind, placebo-controlled phase II/III trial investigating the efficacy of anti-FcRn targeting with efgartigimod as a first-line add-on therapy to IVMP in moderate-to-severe attacks of demyelinating diseases of the central nervous system

2025-523654-13-00Demyelinating diseases

Medizinische Hochschule Hannover

Nervous System Diseases

Germany, Austria

17/06/2026

Phase II

Preventive effect of 5% lidocaine patch on the development of neuropathic pain following an osteoporotic vertebral fracture: A proof-of-concept, controlled, randomized trial

2025-524889-25-00Osteoporotic Fracture

University Hospital Of Clermont-Ferrand

Musculoskeletal Diseases

France

17/06/2026

Phase IV

STOP - Safety and efficacy of a STOPping strategy versus classical maintenance dose of JAK inhibitors in deep remission patients with ulcerative colitis: a randomized controlled trial

2026-525643-32-00ulcerative colitis

DrugsFilgotinib·Tofacitinib·Upadacitinib

Centre Hospitalier Regional De Marseille

Digestive System Diseases

France

17/06/2026

Phase I

A Study to Learn About How Different Forms of Study Medicine Prifetrastat are Taken Up Into the Blood in Healthy Adults

2026-526038-26-00Locally advanced or metastatic ER+/HER2- breast cancer

Pfizer Inc.

Neoplasms

Belgium

17/06/2026

Phase I

Phase 1/1b Study of RNDO-564 in Participants with Advanced Urothelial Cancer

2025-524687-38-00Other Solid Tumors Associated with Nectin-4 Expression, Rel…

Rondo Therapeutics Inc.

Neoplasms

Spain

17/06/2026

Phase I

A phase 1 first-in-human study of a phenylalanine-binding polymer (phelimin) in healthy volunteers and adult, classical PKU patients

2024-519121-38-01Phenylketonuria

Mipsalus ApS

Nutritional and Metabolic Diseases

Denmark

17/06/2026

Phase III

IM0271016: An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants with Pulmonary Fibrosis

2025-522373-10-00Progressive pulmonary fibrosis and Idiopathic pulmonary fib…

DrugAdmilparant

Bristol-Myers Squibb Services Unlimited Company

Respiratory Tract Diseases

Finland, Portugal, Hungary, Ireland, Poland, Greece, France, Belgium, Denmark, Italy, Spain, Netherlands, Austria, Germany

17/06/2026

Phase II

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Nemolizumab in Adult Patients with Systemic Sclerosis, including a 52-Week Main Treatment Period and a 156-Week Extension Treatment Period

2025-522294-11-00Systemic sclerosis

Galderma S.A.

Skin and Connective Tissue Diseases

Poland, Italy, Bulgaria, France, Greece, Spain, Croatia

17/06/2026

Phase I

A First‑in‑Human Phase 1 Study to Investigate the Safety, Tolerability, and PK of AB102 in Healthy Participants

2026-526279-52-00Healthy volunteers

Arcus Biosciences Inc.

Skin and Connective Tissue Diseases

Netherlands

16/06/2026

Phase II

RADICAL-IO: thRee cycles of immunotherApy without raDical therapy In mediCALly InOperable stage I non-small cell lung cancer

2025-524305-32-00Stage I non-small cell lung cancer

DrugCemiplimab

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Respiratory Tract Diseases

Netherlands

16/06/2026

Phase I

Open-label study of BBO-11818 in adult subjects with KRAS mutant cancer

2025-524690-16-00Solid Tumors

Theras Inc.

Neoplasms

Spain, Italy, France

16/06/2026

Phase II

A Phase 2, Open-Label Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)

2025-525124-10-00Duchenne Muscular Dystrophy

DrugsENTR-601-44·ENTR-601-45

Entrada Therapeutics Inc.

Musculoskeletal Diseases

Belgium, Italy, Netherlands, Spain

16/06/2026

Phase I

A Phase 1, Open-Label, Multicenter Study of INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

2025-523130-11-00Advanced solid tumors, Hematological malignancies

Incyte Corp.

Neoplasms

Italy, Belgium, Denmark

16/06/2026

Phase III

A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug vedotin in Combination with Capecitabine with or without Rilvegostomig in First-line Claudin18.2-positive, HER2-negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (CLARITY-Gastric 02)

2024-519787-40-00Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, E…

AstraZeneca AB

Neoplasms

France, Italy, Spain, Hungary, Poland, Belgium, Germany, Netherlands

16/06/2026

Phase I/II

A Phase I/II Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6621, a T Cell-engaging Antibody That Targets STEAP2, CD3, and CD8 in Adult Participants With Metastatic Prostate Cancer (ACTIVATED-4-PC)

2025-520626-37-00Metastatic Prostate Cancer

AstraZeneca AB

Neoplasms

Belgium, Spain, Poland, Italy, Netherlands

16/06/2026

Phase III

A Phase 3, Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completely Resected High-Risk Stage I Non-Small Cell Lung Cancer (INTerpath-014)

2025-522643-18-00Stage I NSCLC

DrugsPembrolizumab Formulated with Berahyaluronidase Alfa·Intismeran autogene

Merck Sharp & Dohme LLC

Neoplasms

Greece, Poland, Italy, Hungary, Germany, Netherlands, France, Spain

16/06/2026

Phase II

A Study to Evaluate the Long-term Safety and Efficacy of Long-acting Antibodies as Single Agents and in Combinations in Participants with Inflammatory Bowel Disease

2025-524640-35-00Ulcerative colitis (Inflammatory Bowel Disease)

DrugsSPYPBO-101·SPY001·SPY002·SPY003

Spyre Therapeutics Inc.

Digestive System Diseases

Croatia, Poland, Austria, Czechia, Italy, Slovakia, Bulgaria, Greece, Belgium, Spain, Hungary, Germany, Lithuania, France, Romania

16/06/2026

Phase III

Achieve - ACetazolamide in patients with Heart failure, to decrease weight and relIEVE symptoms

2025-524344-35-00Heart failure

DrugAcetazolamide

Centre Hospitalier Universitaire De Montpellier

Cardiovascular Diseases

France

15/06/2026

Phase III

A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of each of two dose levels of sarilumab in adults with early polymyalgia rheumatica

2024-511296-15-00Musculoskeletal diseases

Sanofi-Aventis Recherche & Developpement

Musculoskeletal Diseases

France, Netherlands, Germany, Czechia, Belgium, Austria, Hungary, Greece, Spain

15/06/2026

Phase III

An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of BBP-418 (Ribitol) in Participants with Limb-Girdle Muscular Dystrophy 2I/R9 (LGMD2I/R9)

2025-524371-23-00Limb Girdle Muscular Dystrophy (LGMD) Type 2I

DrugRibitol

ML Bio Solutions Inc.

Musculoskeletal Diseases

Germany, Denmark, Netherlands, Italy, Norway

15/06/2026

Phase II

A single arm single center exploratory observational phase II study, aimed to detect long term changes in volume of port-wine macrocheilia and color of port-wine stain in patients undergoing surgery and laser therapy during sirolimus treatment. Quality of life and efficacy and safety of sirolimus will be assessed.

2024-511937-37-01Vascular malfomation

DrugSirolimus

Oslo University Hospital HF

Hemic and Lymphatic Diseases

Norway

15/06/2026

Phase II

A Phase II, Open-label, Multicenter Study Testing Teclistamab in Combination with Pomalidomide Administered in Alternative Fashion in Participants with RRMM, who Received 1 - 3 Prior Lines of Therapy, Including Lenalidomide and Anti-CD38 Therapy

2025-522114-23-00Multiple myeloma (RRMM)

Odense University Hospital

Neoplasms

Finland, Denmark, Estonia, Norway

15/06/2026

Phase IV

Real-World Effectiveness and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy (C3G) or Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN): A Multi-Country Study (PRISMC3)

2025-524487-37-00Primary Immune Complex Membranoproliferative Glomerulonephr…

DrugPegcetacoplan

Swedish Orphan Biovitrum AB (publ)

Immune System Diseases

France, Italy, Spain, Germany, Austria, Belgium, Czechia

15/06/2026

Phase II

Exploratory study evaluating the relevance of [68Ga]Ga-FAPI-46 for staging and identifying progressing patients with transthyretin cardiac amyloidosis

2025-523616-36-00Transthyretin cardiac amyloidosis

Centre Hospitalier Universitaire De Nantes

Diagnosis

France

13/06/2026

Phase III

A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Study of MK-1084 Plus Durvalumab Versus Placebo Plus Durvalumab in Participants With Locally Advanced, Unresected KRAS G12C-Mutant Non-Small Cell Lung Cancer Without Disease Progression Following Definitive Platinum-Based Chemoradiotherapy (KANDLELIT-015)

2025-522038-29-00Locally advanced, unresected (unresectable or medically ino…

DrugsCalderasib·Durvalumab

Merck Sharp & Dohme LLC

Neoplasms

Italy, Netherlands, France, Germany, Spain, Poland, Greece

12/06/2026

Phase I

A Safety Study to Test a New Medicine (ANT3310) Alone and When Taken with an Antibiotic (Meropenem) in Healthy Adult Participants.

2026-526411-11-00Not applicable for phase I study

Antabio

Not possible to specify

France

12/06/2026

Phase III

A Phase 2/3, Randomized, Open-Label, Comparison Study of MK-1045 Versus Blinatumomab in Participants With Relapsed or Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

2025-522267-15-00Relapsed/refractory B-cell Acute Lymphoblastic Leukemia

Merck Sharp & Dohme LLC

Neoplasms

Greece, Netherlands, Sweden, France, Italy, Spain, Denmark

12/06/2026

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-2)

2025-523674-16-00Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Glaxosmithkline Research & Development Limited

Nutritional and Metabolic Diseases

Greece, Germany, Belgium, Netherlands, Poland, Italy, France, Spain, Bulgaria, Austria

12/06/2026

Phase IV

BEAT Fatigue – Benefit of Elevated Administration of Thiamine for Fatigue in Rheumatoid Arthritis: A randomized, double-blind, placebo-controlled trial

2024-519268-41-00Fatigue in rheumatoid arthritis patients

Odense University Hospital

Musculoskeletal Diseases

Denmark

12/06/2026

Phase I

Study to assess the relative bioavailability of Neludolat versus YAZ in healthy female subjects.

2025-524871-22-00Healthy subjects

Pevisal Group Farmaceutici S.r.l.

Reproductive and Urinary Physiological Phenomena

Czechia

12/06/2026

Phase II

A PHASE 2 STUDY OF STRIDE (durvalumab + tremelimumab) With Lenvatinib Versus STRIDE Alone in Patients With Unresectable Hepatocellular Carcinoma (SLIDE-HCC) - HE.2

2025-521608-23-00patients with unrestectable hepatocellular carcinoma (SLIDE…

DrugsTremelimumab·Lenvatinib·Durvalumab

IRCCS Istituto Nazionale Tumori Fondazione Pascale

Neoplasms

Italy

12/06/2026

Phase II

J6Z-MC-IIBD - A Master Protocol for Phase 2, Randomized, Controlled Studies of Multiple Interventions for the Treatment of Adults With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease J6Z-MC-CD01 - A Phase 2, Multicenter, Randomized, Open-Label, Active-Controlled Study to Investigate LY4395089/Mirikizumab Co-administration Compared with Mirikizumab in Adults with Moderately to Severely Active Crohn’s Disease

2025-524112-11-00J6Z-MC-IIBD - Colitis, Ulcerative Crohn Disease J6Z-MC-CD…

DrugMirikizumab

Eli Lilly & Co.

Digestive System Diseases

Italy, Germany, Hungary, Poland, Belgium

11/06/2026

Phase I/II

Phase I-IIa, national, multicenter, clinical trial to evaluate the safety and preliminary efficacy of CAR-T CD19 therapy in patients with refractory lupus nephritis.

2025-522449-23-00Refractory Lupus Nephritis

Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz

Immune System Diseases

Spain

11/06/2026

Phase III

Evaluation of the Non-Inferiority of Topical Chloramphenicol Versus Topical Ciprofloxacin in the Resolution of Otorrhea in Adults With Chronic Suppurative Otitis Media (CSOM) – Protocol OMCOS

2026-525540-15-00chronic suppurative otitis media (CSOM)

Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre

Otorhinolaryngologic Diseases

Spain

11/06/2026

Phase II

A Phase 2, Open-Label, Multicenter, Randomized Study to Evaluate Denikitug as Monotherapy or in Combination With Nivolumab or Chemotherapy in Participants With HER2-Negative, Unresectable, Recurrent, and/or Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas

2025-524095-27-00HER2-negative, unresectable, recurrent, and/or metastatic g…

Gilead Sciences Inc.

Neoplasms

Spain, France

11/06/2026

Phase IV

Efficacy of top-down therapy with mirikizumab versus standard of care with azathioprine in patients with newly diagnosed, moderate-to-severe Crohn’s disease: A 52-week, multicenter, open-label, randomized controlled trial

2026-525191-26-00Crohn’s disease

DrugsAzathioprine·Mirikizumab

Universitaetsklinikum Schleswig-Holstein AöR

Digestive System Diseases

Germany, Poland

11/06/2026

Phase IV

Clinical trial to evaluate the correlation between variation in intestinal lactase activity measured with LacTEST 0.45g and alteration of intestinal barrier integrity and/or intestinal permeability in patients with celiac disease

2026-525518-70-00Patients with celiac disease

Venter Pharma S.L.

Digestive System Diseases

Spain

11/06/2026

Phase I/II

ACTIVATE - Phase 1 Clinical Trial evaluating the combination of Actinomycin D and venetoclax in patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

2025-524728-22-01Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Assistance Publique Hopitaux De Paris

Not possible to specify

France

10/06/2026

Phase III

First adjuvant trial in locally resected aggressive pancreatic neuroendocrine tumors: a randomized phase III investigating the efficacy of systemic chemotherapy (ADJUPANET)

2025-523593-16-00Pancreatic NeuroEndocrine Tumors (PanNET) ; Aggressive stag…

DrugsTemozolomide·Capecitabine

Institut Gustave Roussy

Neoplasms

France

10/06/2026

Phase III

A Phase 3 prospective, randomized, multicenter, active-controlled study to evaluate the efficacy and safety of BV100 plus low-dose polymyxin B compared with colistin plus high-dose ampicillin/sulbactam in the treatment of adult patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex

2025-524092-23-00Hospital-acquired bacterial pneumonia including ventilator-…

Bioversys S.A.S.

Bacterial Infections and Mycoses

Greece, Croatia

10/06/2026

Phase II

J6E-MC-KWAM: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Development Program to Evaluate the Efficacy and Safety of LY4268989 (MORF-057) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (EMERALD-3)

2025-524404-29-00Ulcerative Colitis, Active Severe, Ulcerative Colitis, Acti…

Eli Lilly & Co.

Digestive System Diseases

Latvia, Portugal, Greece, France, Czechia, Italy, Poland, Slovakia, Hungary, Croatia, Lithuania

10/06/2026

Phase I

A clinical trial to learn about the effects of JFI447 and how it shows up in scans compared to FFG233 in people with solid tumors

2025-523665-24-00Patients with metastatic PDAC, NSCLC, HR+/HER2- ductal and …

Novartis Pharma AG

Neoplasms

Denmark

10/06/2026

Phase III

A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of ASP3082 in Combination with mFOLFIRINOX or NALIRIFOX as First-line Treatment in Participants with KRAS G12D-mutated Metastatic Pancreatic Adenocarcinoma

2025-523684-38-00Adult participants with metastatic PDAC with KRAS G12D muta…

Astellas Pharma Global Development Inc.

Neoplasms

Germany, Italy, Spain, Poland, France

10/06/2026

Phase III

Long-term follow-up study of patients who have previously been exposed to UCART19 (allogeneic engineered T-cells expressing a lentiviral-based anti-CD19 chimeric antigen receptor)

2026-526212-37-00Advanced lymphoid leukemia

Institut De Recherches Internationales Servier IRIS

Neoplasms

France

09/06/2026

Phase III

A Phase 2/3 randomized, open-label study of MK-1045 in combination with rituximab in patients with 1L follicular lymphoma.

2025-522777-10-00Follicular Lymphoma

Merck Sharp & Dohme LLC

Neoplasms

France, Spain, Germany, Greece, Italy, Poland

09/06/2026

Phase I

A trial in healthy participants to find out how long JNJ-101556143 stays in and acts on the body when administered as different formulations and under different food conditions

2026-526263-38-00Prostate Cancer

Janssen Cilag International

Neoplasms

Belgium

09/06/2026

Phase IV

DISCO-RA:DIScontinuation of COncomitant disease modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis patients also using TNF inhibitors - a randomized long-term non-inferiority strategy trial

2026-525316-33-00Rheumatoid arthritis

Sint Maartenskliniek Stichting

Immune System Diseases

Netherlands

09/06/2026

Phase III

Accelerate Improvement in Multiple Myeloma for Newly Diagnosed Transplant-Eligible Patients (AugMMent)

2025-523990-40-00Newly diagnosed Multiple Myeloma in patients eligible for s…

Universitaetsklinikum Heidelberg AöR

Hemic and Lymphatic Diseases

Germany

09/06/2026

Phase I/II

A Phase 1/2, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients with Advanced KRAS G12D-Mutant Solid Tumors

2025-523432-39-01Advanced KRAS G12D-Mutant Solid Tumors

Verastem Inc.

Neoplasms

Italy, France, Germany, Belgium, Spain, Netherlands

09/06/2026

Phase III

Randomized, double-blind, parallel-group clinical trial, compared with placebo to evaluate the efficacy and safety of three antibiotic treatment regimens for the eradication of primary P. aeruginosa infection in patients with bronchiectasis

2025-524454-34-00Bronchiectasis

Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau

Respiratory Tract Diseases

Spain

09/06/2026

Phase III

Efanesoctocog alfa treatment in patients with synovitis in congenital hemophilia A: multicenter, randomized, open-label, phase 3 clinical trial

2025-523896-44-00Congenital hemophilia A (HA), Synovitis

DrugEfanesoctocog alfa

GWT-Tud GmbH

Hemic and Lymphatic Diseases

Austria, Germany

08/06/2026

Phase III

A Phase 2b/3, Randomized, Double-Blinded, Placebo Controlled Study ChecKing the Efficacy and Safety of ATAciguat to Slow the Progression of VaLvular DYsfunction in Participants with Moderate Calcific Aortic Valve STenosis (KATALYST-AV)

2025-522176-86-01Moderate Calcific Aortic Valve Stenosis (CAVS)

Kardigan Inc.

Cardiovascular Diseases

Norway, Czechia, Portugal, Austria, Poland, France, Spain

08/06/2026

Phase I/II

A Phase 1b/2 Open-label Study Evaluating different MK-6070 and Ifinatamab Deruxtecan (MK-2400)-based regimens in First-line Extensive Stage Small Cell Lung Cancer

2025-521032-11-00Small cell lung cancer extensive stage

Merck Sharp & Dohme LLC

Neoplasms

Germany, Poland, Greece, Italy, France, Spain

08/06/2026

Phase I

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ST‑905‑AG1 in Healthy Volunteers

2026-525700-10-00Schizophrenia

Syremis Therapeutics Ltd.

Mental Disorders

France

08/06/2026

Phase III

HOVON 182 CLL: Prospective randomized phase 3 study of treatment with rituximab (6 cycles) in combination with 6 or 26 cycles of venetoclax in patients with relapsed or refractory chronic lymphocytic leukemia RED RIVER CLL study: Reduced Duration Rituximab VEnetoclax in Relapsed/refractory CLL

2025-524283-38-00Relapsed or refractory small lymphocytic lymphoma, Relapsed…

Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Hemic and Lymphatic Diseases

Netherlands

08/06/2026

Phase IV

A neuropsychobiological approach to optimize patient selection for GLP-1-based pharmacotherapy for weight management across the binge eating spectrum

2026-526016-36-00obesity

UZ Leuven

Nutritional and Metabolic Diseases

Belgium

08/06/2026

Phase II

A multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase IIb study to assess the efficacy and safety of GIA632 in adult participants with non-segmental vitiligo followed by an extension period

2025-522301-37-00Nonsegmental vitiligo

Novartis Pharma AG

Skin and Connective Tissue Diseases

Germany, Spain, Netherlands, France, Italy

08/06/2026

Phase II

J5D-MC-FPAC: A Phase 2a, Randomized, Multicenter, Double-Blind, Placebo-Controlled Proof of Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants With Severe Alopecia Areata

2025-524727-41-00Alopecia Areata

Eli Lilly & Co.

Immune System Diseases

Poland, Netherlands

08/06/2026

Phase III

PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, NON-INFERIORITY CLINICAL-TRIAL TO ASSESS THE EFFICACY AND SAFETY OF SHORT OUTPATIENT AMOXICILLIN REGIMENS IN CHILDREN WITH ACUTE STREPTOCOCCAL PHARYNGOTONSILLITIS (STOP – TRIAL)

2026-525355-93-00ACUTE STREPTOCOCCAL PHARYNGOTONSILLITIS

DrugAmoxicillin

Fundacion Para La Investigacion Biomedica Hospital Infantil Universitario Nino Jesus

Bacterial Infections and Mycoses

Spain

08/06/2026

Phase II

A Phase 2, Open Label, Multicenter, Randomized Study, to Evaluate the Efficacy and Safety of Denikitug Monotherapy and Denikitug-based Combinations in Participants With Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC).

2025-523984-39-00Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC)

Gilead Sciences Inc.

Neoplasms

Spain, Italy, France

08/06/2026

Phase III

Efficacy of sufentanil in urgent laparoscopic cholecystectomy: An alternative to the usual opioids for postoperative pain?

2026-525783-18-00Laparoscopic cholecystectomy

DrugsSufentanil·Fentanyl

Fundacion Biomedica Galicia Sur

Digestive System Diseases

Spain

08/06/2026

Phase I/II

TSRA196-AAT-201: A Phase 1/2, Open-Label, Multi-Center, Dose Escalation, Dose Expansion, and Single Repeat Dose Study of TSRA-196 in Adults With the PiZZ Genotype Who Have Lung and/or Liver Disease Associated with Severe Alpha-1 Antitrypsin Deficiency

2025-523497-16-00Lung and/or Liver Disease Associated with Alpha-1 Antitryps…

Tessera Therapeutics Inc.

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Ireland, Sweden, Netherlands

08/06/2026

Phase I/II

A PHASE IB/II STUDY TO EVALUATE SAFETY AND EFFICACY OF BEXMARILIMAB IN COMBINATION WITH DOXORUBICIN IN METASTATIC SOFT-TISSUE SARCOMA (BEXAR Study)

2025-525144-18-00Advanced or metastatic histologically confirmed soft tissue…

Medica Scientia Innovation Research S.L.

Neoplasms

Spain

08/06/2026

Phase III

A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody Drug Conjugate (ADC), Compared to Investigator’s Choice Therapy in Participants with Relapsed Small Cell Lung Cancer

2025-522818-23-00Small Cell Lung Cancer (SCLC)

DrugsZL-1310·Topotecan

Zai Lab (US) LLC

Neoplasms

Belgium, Czechia, Germany, Denmark, Greece, Netherlands, Poland, Spain, Austria, Italy, France, Croatia, Romania, Norway

08/06/2026

Phase II

REpurposed drug evaluation for DEceleration of immunE aging & Mitigation of chronic inflammation (REDEEM)

2026-526084-38-00Immune Aging, Chronic inflammation

Radboud universitair medisch centrum Stichting

Immune System Diseases

Netherlands

08/06/2026

Phase II

Radium223 dichloride (223RaCl) in the treatment of symptomatic bone metastases from breast cancer.

2025-524208-31-00Symptomatic bone metastases from breast cancer

DrugsExemestane·Anastrozole·Letrozole

Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone

Neoplasms

Italy

08/06/2026

Phase III

A prospective, open-label, non-randomized, multicentre trial to assess the safety and PD of Cangrelor as procedural platelet inhibitor in paediatric subjects from birth to <18 years of age undergoing diagnostic and/or therapeutic percutaneous vascular procedures for management of congenital heart disease

2025-523109-14-00Congenital Heart Disease

Chiesi Farmaceutici S.p.A.

Cardiovascular Diseases

Netherlands, Germany, Portugal, Austria, Italy

08/06/2026

Phase II

C4531031 - AN INTERVENTIONAL PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, THIRD PARTY-UNBLINDED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF PF-07275315 IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

2024-518587-12-00MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (C…

Pfizer Inc.

Respiratory Tract Diseases

Spain, Germany, Poland, Czechia, Greece, Italy, Bulgaria, France, Hungary

08/06/2026

Phase I

A randomized, multiple ascending doses, clinical trial to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of CV-01 after double-blind, placebo-controlled multiple oral administrations for 2 weeks in healthy volunteers, and multiple oral administrations open-label for 2 weeks in a cohort of participants with drug resistant epilepsy

2026-525478-21-00Drug resistant epilepsy

Nervous System Diseases

Sweden

08/06/2026

Phase IV

OCTAGON:A Phase 4, Single Arm Study to Investigate Oral Corticosteroid Tapering in Adult Patients with Generalized Myasthenia Gravis Treated with Ravulizumab

2025-522555-26-00Generalized Myasthenia Gravis

Alexion Pharmaceuticals Inc.

Nervous System Diseases

Italy, Germany

08/06/2026

Phase IV

PREP-ANCA - Comparison of a strategy based on clinic-biological surveillance versus pre-emptive treatment with rituximab in the event of ANCA (anti-neutrophil cytoplasm antibodies) repositivation in patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)

2025-522049-23-00granulomatosis with polyangiitis and microscopic polyangiit…

DrugsPrednisone·Rituximab

Assistance Publique Hopitaux De Paris

Immune System Diseases

France

08/06/2026

Phase II

An open-label, non-randomized, single center, single dose, exploratory phase II trial of FG001 (an imaging agent) in combination with transoral robotic surgery for oropharyngeal squamous cell carcinoma and neck dissection surgery for oral squamous cell carcinoma with regional lymph node metastases

2025-522845-23-00Oral Squamous Cell Carcinoma with neck metastases, Orophary…

Rigshospitalet

Neoplasms

Denmark

08/06/2026

Phase IV

Measles-mumps-rubella vaccine (MMR) at 6 months of age: Long-term follow-up

2026-526160-21-00Prevention of measles, mumps, and rubella by vaccination

Rigshospitalet

Virus Diseases

Denmark

08/06/2026

Phase I

A study to learn more about how safe BAY 3771249 is and how well it works in people with advanced or metastatic colorectal cancer that has a KRAS G12D mutation

2025-523648-11-00adenocarcinoma of the colon or rectum

Bayer Consumer Care AG

Neoplasms

Finland, Spain, Sweden, Italy, Denmark, Netherlands, Belgium

08/06/2026

Phase I/II

KontRASt-R: An open-label, multi-center, rollover study for participants who have been previously enrolled into a Novartis-sponsored opnurasib (JDQ443) study and are continuing to benefit from opnurasib as a single agent or in combination with other study treatments

2025-523537-26-00Locally advanced or metastatic KRAS G12C-mutated non-small …

Novartis Pharma AG

Neoplasms

Spain, Italy, France, Denmark, Belgium

08/06/2026

Phase II

Phase II, Single-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Evaluate The Safety And Efficacy Of Dasatinib To Reduce HIV-1 Reservoir, Chronic Inflammation, And Immune Senescence In People With HIV On Long-Term Antiretroviral Treatment.

2025-524363-20-01HIV-1 infection

DrugDasatinib

Instituto De Salud Carlos III

Virus Diseases

Spain

08/06/2026

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa in Participants With Biopsy-Confirmed F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-1)

2025-523675-39-00Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Glaxosmithkline Research & Development Limited

Nutritional and Metabolic Diseases

Belgium, Greece, Poland, France, Spain, Bulgaria, Italy, Germany, Austria, Netherlands

08/06/2026

Phase II

Phase II, Placebo-controlled trial of Cannabidiol for the treatment of alcohol dependence (PLACONCANALDE)

2023-504439-42-03alcohol dependence

DrugCannabidiol

Hospital Universitario 12 De Octubre

Behavioral Disciplines and Activities

Spain

08/06/2026

Phase III

OFA-VATS : Impact of opioid free anesthesia on postoperative quality of recovery and analgesia after video or robot assisted thoracic surgery

2025-524240-35-00indication for pulmonary resection surgery (segmentectomy o…

DrugsSufentanil·Remifentanil·Dexmedetomidine

Centre Hospitalier Universitaire De Rennes

Anesthesia and Analgesia

France

05/06/2026

Phase III

ERPPAD - Efficacy in Relapse Prevention: Psilocybin in Alcohol use disorder with Depressive symptoms

2025-525069-65-00Alcohol use disorder, depressive symptoms

Centre Hospitalier Universitaire De Nimes

Mental Disorders

France

05/06/2026

Phase III

PACHA-02_Postoperative hepatic arterial chemotherapy after resection of colorectal liver metastases in patients at high risk of recurrence

2025-523913-27-00Participants with R0/R1 resected liver metastases from colo…

DrugsCalcium levofolinate·Folinic acid·Fluorouracil·Irinotecan

Unicancer

Neoplasms

France

05/06/2026

Phase IV

ANTIMIDIS - Cefazolin mediastinal distribution using microdialysis

2025-521988-13-00Infection prophylaxis

DrugCefazolin

Assistance Publique Hopitaux De Paris

Bacterial Infections and Mycoses

France

05/06/2026

Phase II

Phase IIb Multicenter Randomized Controlled Trial Evaluating the Efficacy of Sivelestat in Patients with Septic Coagulopathy

2025-523397-16-00Septic Coagulopathy

Les Hopitaux Universitaires De Strasbourg

Investigative Techniques

France

05/06/2026

Phase IV

BIOlogical treatment GRAdual Interval Longing in severe Asthma (BIO-GRAIL)

2025-524741-28-00Severe Asthma

DrugsBenralizumab·Mepolizumab·Tezepelumab·Dupilumab

Amsterdam UMC Stichting

Respiratory Tract Diseases

Netherlands

05/06/2026

Phase II

Long-term outcomes and safety of repeated rituximab treatment in psychotic disorders – RITS-LONG

2026-525324-26-00Schizophrenia spectrum disorder (SSD)

DrugRituximab

Region Oerebro Laen

Mental Disorders

Sweden

05/06/2026

Phase III

A randomized double-masked, multicenter, 3-arm, pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 compared to aflibercept (2 mg) in participants with neovascular age-related macular degeneration (NVAMD)

2025-524894-17-00Neovascular age-related macular degeneration (NVAMD)

Eyebiotech Limited

Eye Diseases

Austria, Slovakia, Portugal, Czechia, Hungary, Spain, France, Denmark, Italy, Croatia

05/06/2026

Phase IV

A randomised, double-blind, three parallel-group, placebo controlled superiority trial assessing the effect of intravenous versus oral iron supplementation on physical performance, quality of life and cognitive function in iron deficient FRAIL elderly IndiviDuals with cardiovascular disease (FRAIL-ID trial)

2025-521570-34-00Frailty with Iron Deficiency in Elderly Patients with Cardi…

Wroclaw Medical University

Nutritional and Metabolic Diseases

Poland

05/06/2026

Phase II

Diagnostic Efficacy of 18F-FAPI-74 PET/CT in Patients with Gastric Cancer

2026-526494-42-00Gastric cancer

Varsinais-Suomen hyvinvointialue

Neoplasms

Finland

05/06/2026

Phase II

A Phase 2a Study of SUN-627 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Impact on Measures of Neuroinflammation in the Central Nervous System in Participants With Non-Active Progressive Multiple Sclerosis (SPMS/PPMS)

2026-525817-29-00Multiple Sclerosis; Primary Progressive Multiple Sclerosis;…

Sundance Biosciences Inc.

Nervous System Diseases

Finland

05/06/2026

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2

2025-523912-35-00Narcolepsy Type 2

Alkermes Inc.

Nervous System Diseases

Spain, Netherlands, Belgium, Italy, France, Austria, Czechia, Germany, Sweden, Poland

04/06/2026

Phase IV

Pulmonary Embolism & Anticoagulation Evaluation in Cancer Patient - PEACE

2025-524110-28-00Incidental Subsegmental Pulmonary Embolism in cancer patien…

DrugsDalteparin·Tinzaparin·Edoxaban·Enoxaparin

Region Hovedstaden

Cardiovascular Diseases

Denmark

04/06/2026

Phase III

TicAgreLor versus placebo to prevent cerebral ISCHemia in anEuRysmal low grade SAH A double blinded randomised controlled study TALISCHER - SAH

2023-509795-42-00Aneurysmal subarachnoid hemorrhage

DrugTicagrelor

Centre Hospitalier Universitaire De Toulouse

Nervous System Diseases

France

04/06/2026

Phase I/II

REGENOVAR: A Phase I/II Study of Ubamatamab Plus Carboplatin, Paclitaxel, and Bevacizumab as Salvage Therapy in Ovarian Cancer with Poor Response to First-Line Chemotherapy.

2025-524232-20-00Patients with poor prognostic ovarian cancers based on the …

DrugsUbamatamab·Filgrastim·Paclitaxel·Bevacizumab

Asso De Recherche Cancers Gynecologiques

Neoplasms

France

04/06/2026

Phase I

Bioequivalence of Tramadol retard 200 mg Prolonged-Release Tablets in Healthy Subjects Under Fed Conditions

2026-525780-41-00Not applicable (submitted trial is a bioavailability trial …

Laboratorios Cinfa S.A.

Nervous System Diseases

Czechia

04/06/2026

Phase I

T cell imaging in kidney transplantation (TIK)

2025-522490-11-00Renal allograft rejection

Radboud universitair medisch centrum Stichting

Immune system processes

Netherlands

04/06/2026

Phase I/II

A study on the safety of and immune response to different doses of RSV/hMPV combination and hMPV vaccines in adults

2025-524456-58-00Respiratory Syncytial Virus Infections+Metapneumovirus

GlaxoSmithKline Biologicals

Respiratory Tract Diseases

Belgium

04/06/2026

Phase II

Cosmos Trial: Cerebroprotection Of AST-004 in Mild Complicated Traumatic Brain Injuries

2026-525554-11-00Traumatic brain injury

Astrocyte Pharmaceuticals Inc.

Nervous System Diseases

Netherlands

04/06/2026

Phase III

Prognostic Performance of Quantitative Myocardial Perfusion Imaging Using H2[15O] Positron Emission Tomography in Coronary Artery Disease - The AQUA COR trial

2024-518706-41-01Cardiovascular disease

Vaestra Goetalandsregionen

Diagnosis

Sweden

03/06/2026

Phase I/II

A Phase 1b/2 Study to Evaluate NB-4746 in Participants with Amyotrophic Lateral Sclerosis.

2025-523939-18-00Amyotrofic Lateral Sclerosis (ALS)

DrugRiluzole

Nura Bio Inc.

Nervous System Diseases

Poland, Netherlands, Italy, Spain

03/06/2026

Phase III

Montelukast as disease modifying treatment in mild-moderate Parkinson’s disease, an open-label, phase II extension trial (MONTPARK_OLE)

2026-525906-37-00Parkinson's Disease

DrugMontelukast

Karolinska University Hospital

Nervous System Diseases

Sweden

03/06/2026

Phase III

2025-524575-22-00Neovascular age-related macular degeneration (NVAMD)

Eyebiotech Limited

Eye Diseases

Spain, Poland, Estonia, Latvia, Germany

03/06/2026

Phase I/II

A Phase 1/2, Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamic, and Antitumor Activity of CR-001 in Adult Participants with Locally Advanced or Metastatic Solid Tumors.

2025-523590-42-00Locally Advanced or Metastatic Solid Tumors

Crescent Biopharma Inc.

Neoplasms

Spain, Ireland, Italy, France, Romania

02/06/2026

Phase III

A Randomized Open Label Trial Exploring the Soluble and Imaging Biomarker Dynamic Responses to Tolebrutinib Compared to Rituximab Treatment in Patients with Multiple Sclerosis (MS)

2025-523892-50-00Multiple Sclerosis

DrugRituximab

Region Stockholm – SLSO

Nervous System Diseases

Sweden

02/06/2026

Phase II

Prevention of radiation-induced salivary gland damage by botulinum toxin application in patients with head and neck cancers

2025-524720-22-00patients with head and neck squamous cell carcinoma (HNSCC)

DrugBotulinum toxin type A

Fakultni Nemocnice Kralovske Vinohrady

Otorhinolaryngologic Diseases

Czechia

02/06/2026

Phase I

Randomized, open-label, multiple dose, two-period, two-treatment, cross-over pharmacodynamic study in healthy male and female participants under fasting conditions.

2026-526556-31-00Pharmacodynamic study under fasting condition.

Adamed Pharma S.A.

Cardiovascular Diseases

Czechia

02/06/2026

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

2025-523911-13-00Narcolepsy Type 1

Alkermes Inc.

Nervous System Diseases

Italy, France, Netherlands, Spain, Belgium, Austria, Czechia, Finland, Germany, Sweden, Norway, Poland

02/06/2026

Phase III

Multinational, Interventional, 52-week, Open-label, Single-arm Study to Evaluate the Treatment Outcomes of Anifrolumab 120 mg Subcutaneous Once Weekly in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus (SUNFLOWER)

2025-523670-17-00Systemic lupus erythematosus

AstraZeneca AB

Immune System Diseases

Poland, Germany, Italy, France, Spain

02/06/2026

Phase I

An open label, randomized, multiple-dose, two-treatment, two-period, cross-over bioequivalence study comparing Pyridostigmine Bromide, P.R.Tab, 180 mg/tab, VIANEX S.A., Greece versus Mestinon® retard 180 mg/prolonged-release tablet, Viatris Healthcare GmbH, Germany, in healthy male and female volunteers under fasting conditions.

2025-524219-35-00treatment of myasthenia gravis

Vianex S.A.

Musculoskeletal Diseases

Czechia

02/06/2026

Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS). Derived from the EMA Clinical Trials Information System. Retrieved 4 November 2026. https://priyalifescience.com/clinical-trials-europe?page=2

Query this register directly

GET /api/export.php?register=trials-eu&format=json Try it now →

About this register

This register is built from the EU Clinical Trials Information System (CTIS), run by the European Medicines Agency: the single register for every trial authorised under the EU Clinical Trials Regulation (536/2014). CTIS held 12,757 trial records at the last sync on 03 Nov 2026, 03:17 UTC; this register shows the 2,556 most recently authorised of them, a stated recency window rather than the full archive. The list can be downloaded as CSV or JSON.

How many clinical trials does CTIS hold?

CTIS held 12,757 trial records at the last sync. Of the 2,556 most recently authorised trials shown in this register, 787 are Phase III. Trials are counted by authorisation, not by recruitment status, which CTIS does not publish in the same form as ClinicalTrials.gov.

→

Browse trials by member state

Spain (1075) France (937) Germany (900) Italy (777) Poland (626) Netherlands (548) Belgium (459) Czechia (339) Denmark (323) Hungary (258) Greece (242) Austria (222) Romania (221) Bulgaria (218) Sweden (202)

→

Browse trials by condition

Advanced solid tumors (23) Atopic dermatitis (18) Non-Small Cell Lung Cancer (15) Obesity (14) Parkinson’s disease (14) Multiple sclerosis (13) Rheumatoid arthritis (13) Breast Cancer (11) Ulcerative colitis (11)

Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.